

CONSOLIDATED FINANCIAL REPORT,
SUPPLEMENTARY INFORMATION, UNIFORM
GUIDANCE REPORTS AND SCHEDULE

Mayo Clinic
Years Ended December 31, 2022 and 2021

Ernst & Young LLP



Mayo Clinic

Consolidated Financial Report, Supplementary Information, Uniform Guidance Reports and Schedule

Years Ended December 31, 2022 and 2021

Contents

Independent auditor's report.....	1
Consolidated financial statements	
Consolidated statements of financial position	4
Consolidated statements of activities	5
Consolidated statements of cash flows	6
Notes to consolidated financial statements.....	7
Supplementary Information	
Financial Responsibility Supplemental Schedule required by the U.S. Department of Education	46
Schedule of Expenditures of Federal Awards	47
Schedule of Expenditures of Florida State Financial Assistance	74
Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance	75
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	77
Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, <i>Rules of the Auditor General of the State of Florida</i>	79
Schedule of Findings and Questioned Costs	85

Report of Independent Auditors

Board of Trustees
Mayo Clinic

Opinion

We have audited the consolidated financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2022 and 2021, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Clinic at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Clinic, and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic’s ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to February 17, 2023. The Financial Responsibility Supplemental Schedule required by the U.S. Department of Education and the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, respectively, are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we also have issued our report dated February 17, 2023 on our consideration of the Clinic's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Clinic's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Clinic's internal control over financial reporting and compliance.

Ernst & Young LLP

February 17, 2023, except for the schedules
of expenditures of federal awards and
Florida state financial assistance, for which
the date is August 7, 2023



Consolidated Statements of Financial Position
December 31, 2022 and 2021 (In Millions)

	2022	2021
Assets		
Current assets:		
Cash and cash equivalents	\$ 64	\$ 46
Accounts receivable for medical services	1,842	1,826
Other receivables	759	648
Other current assets	386	317
Total current assets	3,051	2,837
Investments	17,256	18,021
Other long-term assets	3,631	1,407
Property, plant, and equipment, net	5,887	5,410
Total assets	\$ 29,825	\$ 27,675
Liabilities and net assets		
Current liabilities:		
Accounts payable	\$ 752	\$ 768
Accrued payroll	849	818
Accrued employee benefits	176	168
Deferred revenue	64	62
Long-term variable-rate debt	620	620
Other current liabilities	470	509
Total current liabilities	2,931	2,945
Long-term debt, net of current portion	4,121	3,552
Accrued pension and postretirement benefits, net of current portion	819	1,378
Other long-term liabilities	2,083	2,133
Total liabilities	9,954	10,008
Net assets:		
Without donor restrictions	14,808	12,431
With donor restrictions	5,063	5,236
Total net assets	19,871	17,667
Total liabilities and net assets	\$ 29,825	\$ 27,675

See notes to consolidated financial statements.



Consolidated Statements of Activities
Years Ended December 31, 2022 and 2021 (In Millions)

	2022			2021		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains, and other support:						
Medical service revenue	\$ 13,781	\$ —	\$ 13,781	\$ 13,310	\$ —	\$ 13,310
Grants and contracts	666	—	666	613	—	613
Investment return allocated to current activities	250	23	273	217	24	241
Contributions available for current activities	75	268	343	181	253	434
Other	1,227	—	1,227	1,131	—	1,131
Net assets released from restrictions	337	(337)	—	430	(430)	—
Total revenue, gains, and other support	16,336	(46)	16,290	15,882	(153)	15,729
Expenses:						
Salaries and benefits	9,170	—	9,170	8,661	—	8,661
Supplies and services	5,377	—	5,377	4,767	—	4,767
Depreciation and amortization	624	—	624	619	—	619
Facilities	350	—	350	326	—	326
Finance and investment	174	—	174	144	—	144
Total expenses	15,695	—	15,695	14,517	—	14,517
Income (loss) from current activities	641	(46)	595	1,365	(153)	1,212
Noncurrent and other items:						
Contributions not available for current activities, net	(22)	230	208	(22)	371	349
Unallocated investment return, net	(1,382)	(357)	(1,739)	1,432	669	2,101
Income tax expense	(23)	—	(23)	(25)	—	(25)
Benefit credit	175	—	175	61	—	61
Other	129	—	129	(124)	—	(124)
Total noncurrent and other items	(1,123)	(127)	(1,250)	1,322	1,040	2,362
Increase (decrease) in net assets before other changes in net assets	(482)	(173)	(655)	2,687	887	3,574
Pension and other postretirement benefit adjustments	2,859	—	2,859	1,728	—	1,728
Increase (decrease) in net assets	2,377	(173)	2,204	4,415	887	5,302
Net assets at beginning of year	12,431	5,236	17,667	8,016	4,349	12,365
Net assets at end of year	\$ 14,808	\$ 5,063	\$ 19,871	\$ 12,431	\$ 5,236	\$ 17,667

See notes to consolidated financial statements.



Consolidated Statements of Cash Flows
Years Ended December 31, 2022 and 2021 (In Millions)

	2022	2021
Cash flows from operating activities:		
Cash from medical services	\$ 12,827	\$ 12,283
Cash from external lab services	938	957
Cash from grants and contracts	658	616
Cash from benefactors	345	368
Cash from other activities	1,140	1,030
Cash for salaries and benefits	(8,822)	(8,350)
Cash for supplies, services, and facilities	(5,798)	(5,136)
Interest and dividends received	196	222
Interest paid	(144)	(126)
Income taxes paid	(33)	(63)
Net cash provided by operating activities	1,307	1,801
Cash flows from investing activities:		
Purchase of property, plant, and equipment	(1,177)	(861)
Purchases of investments	(7,711)	(6,832)
Sales and maturities from investments	6,838	5,291
Investment in unconsolidated entities	(10)	(43)
Net cash used in investing activities	(2,060)	(2,445)
Cash flows from financing activities:		
Restricted gifts, bequests, and other	208	265
Borrowing on long-term debt	807	500
Payment of long-term debt	(237)	(141)
Payment on leases	(7)	(6)
Net cash provided by financing activities	771	618
Net increase (decrease) in cash and cash equivalents	18	(26)
Cash and cash equivalents at beginning of year	46	72
Cash and cash equivalents at end of year	\$ 64	\$ 46

See notes to consolidated financial statements.

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies

Organization: Mayo Clinic and its Arizona, Florida, Iowa, Minnesota, Wisconsin and international affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

Basis of presentation: Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entities*.

Use of estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Standards:

Effective January 1, 2022, the Clinic adopted FASB Accounting Standards Update (ASU) No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958)*. This ASU required presentation of contributed nonfinancial assets as a separate line in the consolidated statement of activities, apart from contributions of cash or other financial assets. The adoption of this ASU did not materially impact the consolidated financial statements.

Cash and cash equivalents: Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

Accounts receivable for medical services: Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

Inventories: Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

Investments: Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 6). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest, and dividends) is included in the consolidated statements of activities.

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate and natural resources funds) represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a formula, which involves allocating five percent of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its investments over the long term. The unallocated investment return, included in noncurrent and other items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

Property, plant, and equipment: Property, plant, and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from three to fifty years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

Leases: The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant, and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of twelve months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Deferred revenue: Deferred revenue consists of payments received in advance for grant, subscription, and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

Deferred compensation: The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. The compensation deferred under this plan is credited with earnings and losses as determined by the rate of return on investments selected by the plan participants. Each participant is fully vested in all deferred compensation and those earnings credited to their individual accounts. The amounts deferred under this plan is an unsecured obligation of the Clinic. The balances are reflected in investments and other long-term liabilities in the consolidated statements of financial position. The related investment return is reported in unallocated investment return, net, with a corresponding gain/loss representing benefit expense/income reported in the other - noncurrent section of the consolidated statements of activities.

Asset retirement obligations: The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

Net assets: Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net Assets With Donor Restrictions - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Medical service revenue: Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

Grants and contracts: Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement. Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

Charity and uncompensated care: The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was \$54 and \$49 in 2022 and 2021, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled \$613 and \$601 in 2022 and 2021, respectively.

Contributions: The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities. Development expenses of \$54 (\$32 allocated to current and \$22 allocated to noncurrent) and \$48 (\$26 allocated to current and \$22 allocated to noncurrent) were incurred in 2022 and 2021, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification. Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

Income from current activities: The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

Noncontrolling interest in subsidiaries: The Clinic attributed income of \$33 and \$9 for the years ended December 31, 2022 and 2021, respectively, to noncontrolling interests based on the ownership percentage of the noncontrolling interests in certain of the Clinic's consolidated subsidiaries. These amounts are recognized in net assets without donor restrictions on the consolidated statements of financial position. The balance in net assets without donor restrictions as of December 31, 2022 and 2021 was \$68 and \$36, respectively.

Subsequent events: The Clinic evaluated events and transactions occurring subsequent to December 31, 2022 through February 17, 2023, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure.

Notes to Consolidated Financial Statements (In Millions)**Note 2. Liquidity and Availability**

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are composed of the following at December 31:

	2022	2021
Cash and cash equivalents	\$ 64	\$ 46
Accounts receivable	1,842	1,826
Promises to give	319	294
Grants receivable	145	134
Other receivables	295	220
Investments	10,495	11,234
Total financial assets available within one year	<u>\$ 13,160</u>	<u>\$ 13,754</u>

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has \$300 of available lines of credit for working capital (see Note 9 - Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 13 - Endowment, under the Clinic spending policy, \$280 from the endowments was available as of January 1, 2023 and \$247 from the endowments was available at January 1, 2022.

Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2022 and 2021, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years was \$14 and \$6, respectively. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2022 and 2021, was not significant.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available) or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price for the years ended December 31, 2022 and 2021 were not significant. Receivables from third-party payors for final settlements was \$60 and \$10 for December 31, 2022 and December 31, 2021 respectively.

Patients who meet the Clinic's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts which are determined to qualify as charity care are not reported as revenue.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2022 and 2021, are as follows:

	Year Ended December 31, 2022			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,210	\$ 1,089	\$ 1,294	\$ 7,593
Clinic	3,404	844	961	5,209
Senior Care and Nursing Home	15	—	—	15
Other	62	1	—	63
Total patient care service revenue	8,691	1,934	2,255	12,880
External lab	901	—	—	901
Total medical service revenue	<u>\$ 9,592</u>	<u>\$ 1,934</u>	<u>\$ 2,255</u>	<u>\$ 13,781</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,367	\$ 845	\$ 961	\$ 6,173
Services transferred over time	5,225	1,089	1,294	7,608
Total	<u>\$ 9,592</u>	<u>\$ 1,934</u>	<u>\$ 2,255</u>	<u>\$ 13,781</u>

	Year Ended December 31, 2021			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,108	\$ 987	\$ 1,156	\$ 7,251
Clinic	3,353	802	912	5,067
Senior Care and Nursing Home	15	—	—	15
Other	58	1	—	59
Total patient care service revenue	8,534	1,790	2,068	12,392
External lab	918	—	—	918
Total medical service revenue	<u>\$ 9,452</u>	<u>\$ 1,790</u>	<u>\$ 2,068</u>	<u>\$ 13,310</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,329	803	912	\$ 6,044
Services transferred over time	5,123	987	1,156	7,266
Total	<u>\$ 9,452</u>	<u>\$ 1,790</u>	<u>\$ 2,068</u>	<u>\$ 13,310</u>

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. The Clinic's practice is to record certain radiology, pathology, and other hospital related services in the Midwest region as clinic revenue in the amount of \$1,024 and \$973 for the years ended December 31, 2022 and 2021, respectively. Examples of revenue at the time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2022	2021
Medicare	\$ 3,634	\$ 3,377
Medicaid	565	475
Contract	7,916	7,705
Other, including self-pay	1,666	1,753
Total	<u>\$ 13,781</u>	<u>\$ 13,310</u>

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

Financing component:

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instruments categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2022 and 2021.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The following tables present the financial instruments carried at fair value as of December 31, 2022 and 2021, by caption on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

	December 31, 2022				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	\$ 3	\$ —	\$ —	\$ —	\$ 3
Investments:					
Cash and cash equivalents	1,258	72	—	—	1,330
Fixed-income securities:					
U.S. government	—	1,956	—	—	1,956
U.S. government agencies	—	711	—	—	711
U.S. corporate	—	836	—	—	836
Foreign	—	58	—	—	58
Common and preferred stocks:					
U.S.	942	—	—	—	942
Foreign	646	—	20	—	666
Funds:					
Fixed income	327	—	—	—	327
Equities	1,049	662	—	—	1,711
Less securities under lending agreement	(68)	—	—	—	(68)
Investments at NAV	—	—	—	8,719	8,719
Total investments	4,154	4,295	20	8,719	17,188
Investments under securities lending agreement	68	—	—	—	68
Other long-term assets:					
Trust receivables	65	27	112	—	204
Technology-based ventures	—	—	176	—	176
Total other long-term assets	65	27	288	—	380
Total assets at fair value	\$ 4,290	\$ 4,322	\$ 308	\$ 8,719	\$ 17,639
Liabilities:					
Securities lending payable	\$ 3	\$ —	\$ —	\$ —	3
Total liabilities at fair value	\$ 3	\$ —	\$ —	\$ —	3

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2021				Total
	Level 1	Level 2	Level 3	NAV	Fair Value
Assets:					
Securities lending collateral	\$ 6	\$ —	\$ —	\$ —	\$ 6
Investments:					
Cash and cash equivalents	2,593	238	—	—	2,831
Fixed-income securities:					
U.S. government	—	566	—	—	566
U.S. government agencies	—	551	—	—	551
U.S. corporate	—	832	—	—	832
Foreign	—	74	—	—	74
Common and preferred stocks:					
U.S.	1,077	—	—	—	1,077
Foreign	658	—	24	—	682
Funds:					
Fixed income	448	—	—	—	448
Equities	1,021	702	—	—	1,723
Less securities under lending agreement	(95)	—	—	—	(95)
Investments at NAV	—	—	—	9,237	9,237
Total investments	5,702	2,963	24	9,237	17,926
Investments under securities lending agreement	95	—	—	—	95
Other long-term assets:					
Trust receivables	82	32	93	—	207
Technology-based ventures	—	—	138	—	138
Total other long-term assets	82	32	231	—	345
Total assets at fair value	\$ 5,885	\$ 2,995	\$ 255	\$ 9,237	\$ 18,372
Liabilities:					
Securities lending payable	\$ 6	\$ —	\$ —	\$ —	6
Total liabilities at fair value	\$ 6	\$ —	\$ —	\$ —	6

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, composed primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors that would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2022, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,705	\$ 194	Monthly to annually	30–90 days
Private partnerships (b)	5,014	1,744		
Total alternative investments	<u>\$ 8,719</u>	<u>\$ 1,938</u>		

At December 31, 2021, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 4,167	\$ 151	Monthly to annually	30–90 days
Private partnerships (b)	5,070	1,635		
Total alternative investments	<u>\$ 9,237</u>	<u>\$ 1,786</u>		

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic's ownership interest in partners' capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

From time to time, the Clinic invests directly in certain derivative contracts that do not qualify for hedge accounting and are recorded at fair value in investments. Changes in fair value are reported as a component of net unrealized gains or losses in the investment returns. These contracts are used in the Clinic's investment management program to minimize certain investment risks. During the years ended December 31, 2022 and 2021, the realized and unrealized loss from derivative contracts was not significant.

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2022 and 2021 was \$801 (6.3 percent) and \$831 (6.1 percent), respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were \$976 and \$1,044, respectively, at December 31, 2022 and 2021, which includes segregated investments for deferred compensation plans of \$929 and \$1,041 at December 31, 2022 and 2021, respectively.

At December 31, 2022 and 2021, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of \$101 and \$131, respectively.

The Clinic had internally designated investment balances of \$2,978 and \$3,392 at December 31, 2022 and 2021, respectively, for research, education, and capital replacement and expansion.

Notes to Consolidated Financial Statements (In Millions)

Note 5. Investments in Unconsolidated Entities

The Clinic holds certain investments in unconsolidated entities accounted for in accordance with FASB Subtopic 323, *Investments - Equity Method and Joint Ventures*. The investments are presented as other long-term assets in the consolidated statements of financial position. The Clinic's interest in the investment income is reflected in the accompanying consolidated statements of operations.

The following table presents investments in unconsolidated entities as of December 31, 2022 and 2021:

	Ownership Percentage as of December 31, 2022	Carrying Value as of December 31, 2022	Carrying Value as of December 31, 2021
Sheikh Shakhbout Medical City	25%	\$ 155	\$ 89
Medically Home	29%	\$ 49	\$ 57
Other investees	various	\$ 10	\$ 14

The Clinic entered into a joint venture agreement with Abu Dhabi Health Services Company PJSC to operate Sheikh Shakhbout Medical City (SSMC), a 741-bed hospital in the United Arab Emirates. In addition to the joint venture agreement, the Clinic has entered into a hospital expertise agreement, brand license agreement, and research contribution agreement with SSMC. The joint venture has an initial commitment period of twenty years and may be extended by ten years. The Clinic had a \$150 conditional pledge from Sheikh Shakhbout Medical City at December 31, 2022 and 2021.

In July 2021, the Clinic entered into a joint venture agreement with Kaiser Permanente to invest in Medically Home to allow more patients to receive acute care and recovery services in the comfort, convenience, and safety of their homes.

The summarized financial position and results of operations for significant entities accounted for under the equity method as of and for the years ended consisted of the following:

	2022	2021
As of December 31		
Total assets	\$ 920	\$ 794
Total liabilities	\$ 222	\$ 194
Partners equity/net assets	\$ 698	\$ 600
Year Ended December 31		
Total revenue	\$ 524	\$ 440
Loss from current activities	\$ (64)	\$ (65)

Note 6. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit. Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

Notes to Consolidated Financial Statements (In Millions)

Note 6. Securities Lending (Continued)

At December 31, 2022 and 2021, the aggregate market value of securities on loan under securities lending agreements totaled \$68 and \$95, respectively, and the total value of the collateral supporting the securities was \$70 and \$98, respectively, which represents 103% of the value of the securities on loan at December 31, 2022 and 2021. The cash portion of the collateral supporting the securities as of December 31, 2022 and 2021 was \$3 and \$6, respectively. The cash portion is presented in other current assets and other current liabilities in the consolidated statements of financial position. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

Note 7. Property, Plant, and Equipment, Net

Property, plant, and equipment, net, at December 31 consisted of the following:

	2022	2021
Land	\$ 580	\$ 489
Buildings and improvements	7,322	6,935
Furniture and equipment	4,633	4,347
	12,535	11,771
Accumulated depreciation and amortization	(7,414)	(6,899)
	5,121	4,872
Construction in progress	766	538
Total property, plant, and equipment	\$ 5,887	\$ 5,410

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was \$893 and \$874 at December 31, 2022 and 2021, respectively. The total accumulated amortization was \$647 and \$581 at December 31, 2022 and 2021, respectively. Amortization expense for capitalized software was \$74 and \$80 for 2022 and 2021, respectively.

Note 8. Income Taxes

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income. The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2018 through 2020 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Internal Revenue Service (IRS) performed an examination of the tax and information returns of the Clinic and two subsidiaries and ultimately assessed \$12 in taxes for years 2003-2012. The results of this audit were ultimately litigated in the U.S. District Court. On August 6, 2019, the Court issued a summary judgment in favor of the Clinic. The IRS appealed this decision and on May 13, 2021, the Eighth Circuit Court of Appeals reversed the summary judgment and remanded the case to the U.S. District Court for

Notes to Consolidated Financial Statements (In Millions)

Note 8. Income Taxes (Continued)

trial. The case was tried in 2022 and the U.S. District Court issued a judgment in favor of the Clinic on December 9, 2022. No adjustment has been made to unrecognized tax benefits as a result of the ruling due to the IRS having until February 2023 to appeal.

The Clinic has reduced the reserve for uncertain tax positions by \$2, including interest and penalties, during the year ended December 31, 2022. As of December 31, 2022 and 2021, the reserve totaled \$11 and \$13, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2022	2021
Current—federal	\$ 23	\$ 21
Current—state	6	5
	29	26
Deferred—U.S. domestic	(6)	(1)
Total	\$ 23	\$ 25

Cash payments for income taxes were \$33 and \$63 for the years ended December 31, 2022 and 2021, respectively.

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2022	2021
Deferred compensation	\$ 9	\$ 13
Pension	—	9
Postretirement benefits	2	6
Net operating loss	6	18
Other	6	8
Total deferred tax asset	23	54
Deferred tax liability	(2)	(4)
Valuation allowance	(10)	(14)
Net deferred tax asset	\$ 11	\$ 36

The Clinic had federal net operating losses of \$20 and \$51 at December 31, 2022 and 2021, respectively.

Notes to Consolidated Financial Statements (In Millions)

Note 8. Income Taxes (Continued)

The Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017 repealed Net Operating Loss (NOL) carrybacks while permitting indefinite carryforwards. The Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020 temporarily suspended TCJA repeal of NOL carrybacks allowing for NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to the five taxable years preceding the taxable year of such loss. During 2022 the Clinic was able to utilize \$50 of the NOLs arising in tax years beginning after December 31, 2018 and before January 1, 2022. Of the remaining NOLS, \$9 will be carried back and the remaining \$11 will be carried forward.

Notes to Consolidated Financial Statements (In Millions)

Note 9. Financing

Long-term debt at December 31 consisted of the following:

		2022	2021
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 1.27% in 2022 and 0.08% in 2021), principal due in varying amounts from 2028 through 2052	Variable	\$ 545	\$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2022 through 2032	Fixed	163	200
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	130
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed rate of interest of 4.00%, principal due in varying amounts from 2044 through 2048	Fixed	200	400
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with fixed interest rate of 5.00%, an effective rate of 2.97% in 2022 and 2021 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of \$46 in 2022 and \$50 in 2021)	Fixed	220	220
City of Rochester, Minnesota Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.25% to 5.00%, an effective rate of 3.74% in 2022 after amortization of premium principal due in varying amounts from 2039 through 2057 (unamortized net premium of \$16 in 2022)	Fixed	289	—
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.96% in 2022 and 0.02% in 2021), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 1.32% in 2022 and 0.13% in 2021), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.20% to 4.13%, principal due in varying amounts from 2039 through 2061	Fixed	1,450	1,450
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.80% to 4.71%, principal due in varying amounts from 2025 through 2062	Fixed	1,115	915
The Industrial Development Authority of the City of Phoenix, Arizona Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.75% to 4.00%, an effective rate of 3.80% in 2022 after amortization of premium, principal due in varying amounts from 2053 to 2057 (unamortized net premium of \$3 in 2022)	Fixed	298	—
Other notes payable		12	12
Unamortized discounts and premiums, net		66	46
Debt issuance cost		(16)	(13)
		4,777	4,210
Long-term variable-rate debt classified as current		(620)	(620)
Current maturities included in other current liabilities		(36)	(38)
Long-term debt, net of current portion		\$ 4,121	\$ 3,552

Notes to Consolidated Financial Statements (In Millions)

Note 9. Financing (Continued)

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2022, the \$850 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of \$230 of which \$140 will expire in January 2024 and \$90 will expire in January 2025. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2023. The Clinic has provided self-liquidity for the remaining \$620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The \$220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2023 to 2058 at the option of the Clinic, at a redemption price of 100 percent of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

In April 2021, the Clinic issued bonds in the amount of \$500 with a 3.20 percent fixed rate of interest. The bonds are due in 2061 and will be used for general corporate purposes.

On April 12, 2022 the Clinic issued fixed rate bonds in the amount of \$587 (\$200 refunding and \$387 new debt issuance) at various coupon rates yielding 3.76 percent to maturity. The bonds are due in 2057 and the new debt will be used for construction projects.

On May 5, 2022, the Clinic entered into a private placement debt agreement with an insurance company for \$200 at 3.26 percent maturing in 2058. The funds will be used for general corporate purposes.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, \$620 may be due in 2023 and \$230 may be due in years from 2024 to 2025.

Years ending December 31:

2023	\$	36
2024		18
2025		105
2026		5
2027		105

Interest payments on long-term debt, net of amounts capitalized for 2022 and 2021, totaled \$132 and \$118, respectively. The amount of interest capitalized, net of related interest income, was \$8 and \$3 during 2022 and 2021. Interest expense totaled \$144 and \$121 for 2022 and 2021, respectively.

At December 31, 2022 and 2021, the Clinic had unsecured lines of credit available with banks that totaled \$530, with varying renewable terms and interest up to 2.50 percent over various published rates. There were no amounts drawn during the years ended December 31, 2022 and 2021.

Notes to Consolidated Financial Statements (In Millions)

Note 10. Leases

At December 31, 2022 and 2021, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Total lease expense for the years ended December 31 consisted of the following:

	2022	2021
Operating lease expense	\$ 34	\$ 34
Finance lease expense:		
Amortization of right-of-use assets	\$ 6	\$ 10
Interest on lease liabilities	1	1
Total finance lease expense	\$ 7	\$ 11
Short-term lease expense	\$ 28	\$ 24

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2022	2021
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 60	\$ 55
Operating cash flows for finance leases	\$ 1	\$ 1
Financing cash flows for finance leases	\$ 7	\$ 6
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 18	\$ 21
Finance leases	\$ 4	\$ 4

Consolidated supplemental statement of financial position information related to leases as of the years ended December 31 consisted of the following:

	2022	2021
Operating leases:		
Right-of-use assets	\$ 141	\$ 151
Other current liabilities	\$ 23	\$ 25
Other long-term liabilities	123	131
Total operating lease liabilities	\$ 146	\$ 156

Notes to Consolidated Financial Statements (In Millions)

Note 10. Leases (Continued)

	2022	2021
Finance leases:		
Property, plant, and equipment, gross	\$ 57	\$ 62
Accumulated depreciation	36	38
Property, plant, and equipment, net	<u>\$ 21</u>	<u>\$ 24</u>
Other current liabilities	\$ 6	\$ 6
Other long-term liabilities	—	16
Total finance lease liabilities	<u>\$ 6</u>	<u>\$ 22</u>
Weighted average remaining lease years:		
Operating leases	9.22	9.85
Finance leases	4.14	4.70
Weighted average discount rate:		
Operating leases	3.35 %	3.37 %
Finance leases	2.98 %	3.04 %

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2023	\$ 27	\$ 7
2024	24	5
2025	20	3
2026	18	2
2027	15	1
Thereafter	70	2
Minimum lease payments	<u>174</u>	<u>20</u>
Less amount representing interest	28	1
Net minimum lease payments	<u>\$ 146</u>	<u>\$ 19</u>

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)**

Note 11. Board-Designated Funds

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2022	2021
Research	\$ 1,365	\$ 1,545
Education	312	358
Buildings and equipment	3	4
Charity care	12	14
Clinical	162	190
Other	1,124	1,281
Total designation for specified purpose	<u>\$ 2,978</u>	<u>\$ 3,392</u>

At December 31, board designated funds were classified as follows:

	2022	2021
Quasi-endowments	\$ 2,830	\$ 3,218
Professional liability reserve	119	141
Other	\$ 29	\$ 33
Total	<u>\$ 2,978</u>	<u>\$ 3,392</u>

Notes to Consolidated Financial Statements (In Millions)

Note 12. Net Assets with Donor Restrictions

The Clinic receives contributions in support of research, education, and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2022	2021
Subject to expenditure for specified purposes:		
Research	\$ 582	\$ 497
Education	59	46
Buildings and equipment	245	174
Charity care	30	30
Clinical	74	65
Other	30	53
Total expenditure for specified purposes	1,020	865
Subject to passage of time:		
Pledges and trusts	642	649
Endowments:		
Perpetual in nature:		
Research	1,233	1,140
Education	304	270
Charity care	14	14
Clinical	222	215
Other	31	33
Pledges and trusts	270	274
Total perpetual in nature	2,074	1,946
Subject to endowment spending policy:		
Research	745	1,028
Education	342	433
Charity care	48	59
Clinical	152	206
Other	40	50
Total subject to endowment spending policy	1,327	1,776
Total endowments	3,401	3,722
Total net assets with donor restrictions	\$ 5,063	\$ 5,236

Notes to Consolidated Financial Statements (In Millions)**Note 12. Net Assets with Donor Restrictions (Continued)**

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2022	2021
Research	\$ 180	\$ 188
Education	25	22
Buildings and equipment	36	197
Other	96	23
Total net assets released from donor restrictions	<u>\$ 337</u>	<u>\$ 430</u>

Note 13. Endowment

The Clinic's endowment consists of approximately 2,300 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to re-designate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least five percent over the long term. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater

Notes to Consolidated Financial Statements (In Millions)

Note 13. Endowment (Continued)

emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year five percent of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2022, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,401	\$ 3,401
Quasi-endowments	2,830	—	2,830
Total funds	<u>\$ 2,830</u>	<u>\$ 3,401</u>	<u>\$ 6,231</u>

Changes in endowment net assets for the year ended December 31, 2022, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 3,218	\$ 3,722	\$ 6,940
Investment return:			
Investment income	32	34	66
Net depreciation (realized and unrealized)	(330)	(356)	(686)
Total investment return	<u>(298)</u>	<u>(322)</u>	<u>(620)</u>
Contributions	<u>—</u>	<u>128</u>	<u>128</u>
Appropriation of endowment assets for expenditure	<u>(146)</u>	<u>(127)</u>	<u>(273)</u>
Other changes:			
Transfers to create quasi-endowments	56		56
Endowment net assets, end of year	<u>\$ 2,830</u>	<u>\$ 3,401</u>	<u>\$ 6,231</u>

Notes to Consolidated Financial Statements (In Millions)**Note 13. Endowment (Continued)**

At December 31, 2021, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,722	\$ 3,722
Quasi-endowments	3,218	—	3,218
Total funds	<u>\$ 3,218</u>	<u>\$ 3,722</u>	<u>\$ 6,940</u>

Changes in endowment net assets for the year ended December 31, 2021, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	<u>\$ 2,694</u>	<u>\$ 3,037</u>	<u>\$ 5,731</u>
Investment return:			
Investment income	40	42	82
Net appreciation (realized and unrealized)	581	640	1,221
Total investment return	<u>621</u>	<u>682</u>	<u>1,303</u>
Contributions	<u>—</u>	<u>108</u>	<u>108</u>
Appropriation of endowment assets for expenditure	<u>(119)</u>	<u>(105)</u>	<u>(224)</u>
Other changes:			
Transfers to create quasi endowments	22	—	22
Endowment net assets, end of year	<u>\$ 3,218</u>	<u>\$ 3,722</u>	<u>\$ 6,940</u>

Note 14. Promises to Give

At December 31, outstanding pledges from various corporations, foundations, and individuals, included in other receivables and other long-term assets, were as follows:

	2022	2021
Pledges due:		
In less than one year	\$ 319	\$ 294
In one to five years	367	399
In more than five years	64	35
	<u>750</u>	<u>728</u>
Allowance for uncollectible pledges and discounts	<u>(38)</u>	<u>(34)</u>
Total	<u>\$ 712</u>	<u>\$ 694</u>

Notes to Consolidated Financial Statements (In Millions)

Note 14. Promises to Give (Continued)

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1 percent to 6 percent, that is commensurate with the pledges due dates and established in the year the pledge is received.

The Clinic has received interests in various trusts, primarily split-interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 3.12 percent and 2.91 percent at December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was \$204 and \$207 at December 31, 2022 and 2021, respectively.

Note 15. Functional Expenses

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2022 and 2021 supported the following programs and functions:

2022								
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses
Salaries and benefits	\$ 7,664	\$ 197	\$ 690	\$ 343	\$ 210	\$ 19	\$ 47	\$ 9,170
Supplies and services	3,789	1,073	280	72	62	11	90	5,377
Depreciation and amortization	512	8	69	10	22	1	2	624
Facilities	268	5	18	12	44	1	2	350
Finance and investment	152	9	18	2	2	—	(9)	174
Total	\$ 12,385	\$ 1,292	\$ 1,075	\$ 439	\$ 340	\$ 32	\$ 132	\$ 15,695

2021								
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses
Salaries and benefits	\$ 7,330	\$ 187	\$ 653	\$ 331	\$ 103	\$ 16	\$ 41	\$ 8,661
Supplies and services	3,299	1,048	258	61	24	8	69	4,767
Depreciation and amortization	515	8	66	11	15	1	3	619
Facilities	264	4	18	12	26	1	1	326
Finance and investment	150	3	18	1	1	—	(29)	144
Total	\$ 11,558	\$ 1,250	\$ 1,013	\$ 416	\$ 169	\$ 26	\$ 85	\$ 14,517

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2022 and 2021, are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of \$137 and \$3,053 and unrecognized prior service benefit of \$63 and \$109. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed ten percent of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2022 and 2021 included the following:

	2022	2021
Current-year actuarial gain	\$ 2,659	\$ 1,440
Amortization of actuarial loss	246	338
Amortization of prior service credit	(46)	(50)
Pension and other postretirement benefit adjustments	<u>\$ 2,859</u>	<u>\$ 1,728</u>

Pension plans:

Obligations and funded status: The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

	2022	2021
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$ 12,194	\$ 12,360
Service cost	690	691
Interest cost	370	350
Actuarial (gain) loss	(4,381)	(302)
Benefits paid	(1,058)	(905)
Settlements	(6)	—
Estimated benefit obligation at end of year	<u>\$ 7,809</u>	<u>\$ 12,194</u>
Change in plan assets:		
Fair value of plan assets, beginning of year	\$ 11,903	\$ 10,642
Actual return on plan assets	(1,188)	1,793
Employer contributions	314	373
Benefits paid	(1,058)	(905)
Settlements	(6)	—
Fair value of plan assets at end of year	<u>\$ 9,965</u>	<u>\$ 11,903</u>

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

	2022	2021
Funded status of the plans	\$ 2,156	\$ (291)
Accumulated benefit obligation	\$ (7,361)	\$ (11,441)

Amounts recognized in the consolidated statements of financial position consist of the following at December 31:

	2022	2021
Noncurrent assets	\$ 2,164	\$ —
Noncurrent liabilities	\$ (8)	\$ (291)
Net amount recognized	\$ 2,156	\$ (291)

Components of net periodic benefit cost are as follows for the years ended December 31:

	2022	2021
Service cost	\$ 690	\$ 691
Interest cost	370	350
Expected return on plan assets	(781)	(732)
Amortization of unrecognized:		
Prior service benefit	(50)	(50)
Net actuarial loss	226	306
Settlement	2	—
Net periodic benefit cost	\$ 457	\$ 565

Plan assets: The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds \$9,864 of the \$9,965 in combined plan assets at December 31, 2022, and \$11,765 of the \$11,903 in combined plan assets at December 31, 2021. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5 percent. The portfolio's target fixed-income exposure is 17.5 percent. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 30 percent (with a target allocation of 22.5 percent), and exposure to absolute return strategies is limited to a maximum of 35 percent (with a target of 27.5 percent). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

The fair values of the Plan's assets at December 31, 2022, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 162	\$ 4	\$ —	\$ —	\$ 166
Fixed income securities:					
U.S. government	—	95	—	—	95
U.S. government agencies	—	155	—	—	155
U.S. corporate	—	316	—	—	316
Foreign	—	36	—	—	36
Common and preferred stocks:					
U.S.	777	—	—	—	777
Foreign	479	—	—	—	479
Funds:					
Fixed income	61	—	—	—	61
Equities	34	637	—	—	671
Foreign	47	1	—	—	48
Investments at NAV	—	—	—	7,060	7,060
Total investments	\$ 1,560	\$ 1,244	\$ —	\$ 7,060	\$ 9,864

The fair values of the Plan's assets at December 31, 2021, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 518	\$ 61	\$ —	\$ —	\$ 579
Fixed income securities:					
U.S. government	—	170	—	—	170
U.S. government agencies	—	120	—	—	120
U.S. corporate	—	400	—	—	400
Foreign	—	52	—	—	52
Common and preferred stocks:					
U.S.	1,077	—	—	—	1,077
Foreign	645	—	—	—	645
Funds:					
Fixed income	114	—	—	—	114
Equities	65	718	—	—	783
Foreign	69	—	—	—	69
Investments at NAV	—	—	—	7,756	7,756
Total investments	\$ 2,488	\$ 1,521	\$ —	\$ 7,756	\$ 11,765

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2022 or 2021.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2022, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,493	\$ 116	Monthly to annually	30–90 days
Private partnerships (b)	3,567	1,369		
	<u>\$ 7,060</u>	<u>\$ 1,485</u>		

At December 31, 2021, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,996	\$ 151	Monthly to annually	30–90 days
Private partnerships (b)	3,760	1,245		
	<u>\$ 7,756</u>	<u>\$ 1,396</u>		

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry "lockup" restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period,

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan's ownership interest in partners' capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2023.

Other postretirement benefits:

Obligations and funded status: A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

	2022	2021
Change in projected benefit obligation:		
Benefit obligation at beginning of year	\$ 1,138	\$ 1,228
Service cost	7	9
Interest cost	34	32
Plan participants contributions	41	35
Medicare subsidy	2	3
Actuarial (gain)	(255)	(82)
Benefits paid	(100)	(87)
Estimated benefit obligation at end of year	<u>\$ 867</u>	<u>\$ 1,138</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ —	\$ —
Employer contributions	59	52
Plan participants contributions	41	35
Benefits paid	(100)	(87)
Fair value of plan assets at end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status of the plan	<u>\$ (867)</u>	<u>\$ (1,138)</u>

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2022	2021
Current liabilities	\$ (56)	\$ (51)
Noncurrent liabilities	(811)	(1,087)
Net amount recognized	<u>\$ (867)</u>	<u>\$ (1,138)</u>

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2022	2021
Service cost	\$ 7	\$ 9
Interest cost	34	32
Amortization of:		
Unrecognized prior service benefit	4	—
Unrecognized net actuarial loss	20	32
Net periodic benefit cost for other postretirement benefits	<u>\$ 65</u>	<u>\$ 73</u>

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts:

Years ending December 31:

2023	\$ 3
2024	3
2025	3
2026	3
2027	3
2028–2032	16

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50 percent.

Pension and postretirement benefits:

Assumptions: Weighted average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2022	2021	2022	2021
Discount rate	5.77%	3.12%	5.68%	3.04%
Rate of compensation increase	3.67%	3.72%	N/A	N/A

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

Weighted-average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2022	2021	2022	2021
Discount rate	3.12%	2.91%	3.04%	2.70%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.72%	3.70%	N/A	N/A

The change in the discount rate from 3.12% to 5.77% for the pension plans and from 3.04% to 5.68% for the other postretirement plans had the net effect of decreasing the projected benefit obligations by \$5,222 for the year ended December 31, 2022.

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

Cash flows:

Contributions: The Clinic expects to contribute \$283 to its pension plans in 2023.

Estimated future benefit payments: The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2023	\$ 499	\$ 58
2024	508	59
2025	526	60
2026	544	62
2027	566	63
2028–2032	3,019	325

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was \$131 and \$124 for 2022 and 2021, respectively.

Note 17. General and Professional Liability Insurance

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

Notes to Consolidated Financial Statements (In Millions)**Note 17. General and Professional Liability Insurance (Continued)**

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was \$159 and \$133 at December 31, 2022 and 2021, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Activity in the liability is summarized as follows for the years ended December 31:

	2022	2021
Balance, beginning of year	\$ 133	\$ 118
Incurred related to captive insurance company liability:		
Current year	30	29
Prior years	12	—
Total incurred	42	29
Paid related to captive insurance company liability:		
Current year	(1)	(2)
Prior years	(24)	(10)
Total paid	(25)	(12)
Net change in self-insurance liability	9	(2)
Balance, end of year	\$ 159	\$ 133

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities

At December 31, other receivables consisted of the following:

	2022	2021
Pledges receivable	\$ 319	\$ 294
Grants receivable	145	134
Pharmacy receivable	58	26
Rebates receivable	34	38
Interest receivable	28	16
Royalty receivable	25	15
Other tax receivable	7	33
Other	143	92
Total other receivables	\$ 759	\$ 648

Notes to Consolidated Financial Statements (In Millions)

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other current assets consisted of the following:

	2022	2021
Inventories	\$ 218	\$ 203
Prepaid expenses	166	108
Other	2	6
Total other current assets	<u>\$ 386</u>	<u>\$ 317</u>

At December 31, other long-term assets consisted of the following:

	2022	2021
Pension asset	\$ 2,164	\$ —
Pledges receivable	393	400
Investments in unconsolidated entities	214	160
Trust receivables	204	207
Oil and gas interests	199	191
Technology-based ventures	176	138
Operating lease right-of-use asset	141	151
Notes receivable	29	16
Prepaid maintenance	23	14
Long-term portion of deferred tax asset	11	36
Other	77	94
Total other long-term assets	<u>\$ 3,631</u>	<u>\$ 1,407</u>

Notes to Consolidated Financial Statements (In Millions)**Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)**

At December 31, other current liabilities consisted of the following:

	2022	2021
Other taxes	\$ 87	\$ 83
Current portion of long-term disability	49	42
Current portion of professional and general liability	43	38
Current maturities of long-term debt	36	38
Short-term disability	30	36
Real estate tax accrual	28	28
Refunds/recoupments	24	21
Operating lease liability	23	25
Accrued interest	20	15
Oil and gas liability	15	81
Medicare settlements liability	13	34
Current portion of workers' compensation liability	11	11
Finance lease liability	6	6
Other	85	51
Total other current liabilities	<u>\$ 470</u>	<u>\$ 509</u>

At December 31, other long-term liabilities consisted of the following:

	2022	2021
Deferred compensation	\$ 929	\$ 1,041
Long-term disability	224	226
Deferred gain	135	74
Operating lease liability	123	131
Professional and general liability	116	95
Electronic medical record	96	101
Retirement community obligations	85	86
Gift annuities	65	67
Financing obligations	60	53
Trust obligations	57	55
Asset retirement obligation	55	55
Workers' compensation liability	32	32
Contract deposit	22	22
Finance lease liability	—	16
Other	84	79
Total other long-term liabilities	<u>\$ 2,083</u>	<u>\$ 2,133</u>

Notes to Consolidated Financial Statements (In Millions)**Note 19. Other Revenue**

For the years ended December 31, other revenue consisted of the following:

	2022	2021
Retail pharmacy sales	\$ 475	\$ 436
Oil and gas producing activities	156	101
Royalties	130	166
Retail stores	71	67
Graduate medical and other education revenue	46	35
Technology commercialization, health information, and medical products	43	52
Cafeteria revenue	32	29
Provider relief funds and other support	—	1
Other	274	244
Total other revenue	<u>\$ 1,227</u>	<u>\$ 1,131</u>

Note 20. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2022 is \$1,677, all of which is expected to be expended over the next three to five years.

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

Note 21. COVID-19

In March 2020, the World Health Organization declared the novel coronavirus disease (COVID-19) a pandemic. The Center for Disease Control confirmed its spread to the United States and declared a national public health emergency. The Clinic was well-prepared and continues to treat patients with COVID-19 across the organization, especially those with serious or complex medical conditions. However, COVID-19 could still negatively affect the operating margins and financial results of the Clinic, as the duration of the pandemic is unknown.

Notes to Consolidated Financial Statements (In Millions)

Note 22. U.S. Department of Education Financial Responsibility Ratio Information

The following information is required by the U.S. Department of Education for the years ended December 31,

	2022	2021
Net assets with temporary donor restrictions	\$ 2,989	\$ 3,290
Intangible assets	\$ 1	\$ 1
Post-employment and retirement liabilities:		
Accrued pension and postretirement benefits, net of current portion	\$ 819	\$ 1,378
Postretirement benefits, current portion	56	51
Total post-employment and retirement liabilities	\$ 875	\$ 1,429
Property, plant, and equipment, including construction in progress and right-of-use asset, net of accumulated depreciation:		
Property, plant, and equipment, net	\$ 5,887	\$ 5,410
Right-of-use asset	141	151
Total property, plant, and equipment, including construction in progress and right-of-use asset, net of accumulated depreciation	\$ 6,028	\$ 5,561
Long-term debt obtained for long term purposes:		
Long-term debt	\$ 4,777	\$ 4,210
Operating lease liabilities	146	156
Finance lease liabilities	6	22
Total long-term debt obtained for long term purposes	\$ 4,929	\$ 4,388
Expenses and losses without donor restrictions:		
Operating expenses	\$ 15,695	\$ 14,517
Contributions not available for current activities, net	22	22
Income tax expense	23	25
Other	—	125
Unallocated investment loss, net	1,382	—
Total expenses and losses without donor restrictions	\$ 17,122	\$ 14,689
Revenue without donor restrictions:		
Total revenue, gains, and other support	\$ 16,336	\$ 15,882
Unallocated investment return, net	—	1,432
Benefit credit	175	61
Pension and other postretirement benefit adjustments	2,859	1,728
Other	129	1
Total revenue without donor restrictions	\$ 19,499	\$ 19,104

The Clinic does not have any material related party transactions to report for 2022 and 2021.

Supplementary Information

Mayo Clinic

Financial Responsibility Supplemental Schedule Required by the U.S. Department of Education Year Ended December 31, 2022 (In Millions)

Ratio Element	Reference to Financial Statements or Notes	2022
Primary Reserve Ratio		
Expendable Net Assets		
Net assets without donor restrictions	Consolidated Statements of Financial Position	\$ 14,808
Net assets with restrictions	Note 22 - U.S. Department of Education	2,989
Term endowments with donor restrictions	Note 12 - Net Assets with Donor Restrictions	1,327
Intangible assets	Note 22 - U.S. Department of Education	1
Property, plant, and equipment, including construction in progress, and right of use asset, net of accumulated depreciation	Note 22 - U.S. Department of Education	6,028
Long-term debt obtained for long term purposes	Note 22 - U.S. Department of Education	4,929
Post-employment and retirement liabilities	Note 22 - U.S. Department of Education	875
Total Expenses and Losses		
Total expenses and losses without donor restrictions	Note 22 - U.S. Department of Education	17,122
Equity Ratio		
Modified Net Assets		
Net assets with and without donor restrictions	Consolidated Statements of Financial Position	19,871
Intangible assets	Note 22 - U.S. Department of Education	1
Modified Assets		
Total assets	Consolidated Statements of Financial Position	29,825
Intangible assets	Note 22 - U.S. Department of Education	1
Net Income Ratio		
Change in net assets without donor restrictions	Consolidated Statements of Activities	2,377
Total revenue without donor restrictions	Note 22 - U.S. Department of Education	19,499

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF DEFENSE									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		NATIONAL MARROW DONOR PROGRAM	BMT CTN 1702		\$62,438	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		NATIONAL MARROW DONOR PROGRAM	BMT CTN 1703/1801		\$438	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-D-7001				\$171,496	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2007			\$369,203	\$2,020,648	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017			\$220,845	\$1,882,012	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017				\$900,399	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2019				\$124,990	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2726				\$615,928	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-22-C-2019				\$2,364	\$5,780,713	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CEDARS SINAI MEDICAL CENTER	W81XWH-0317		\$74,536	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-0810-01			\$160,485	\$272,713	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0115				\$81,382	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		BRIGHAM AND WOMEN'S HOSPITAL	W81XWH-15-1-0269		\$66,106	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0293			\$154,000	\$672,438	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF ALABAMA AT BIRMINGHAM	W81XWH-15-1-0705		\$26,440	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0265				\$199,510	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0266				\$222,579	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0268				\$68,933	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0269				\$263,104	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0540				\$256,945	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0248				\$60,648	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0249				\$282,630	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		MASSACHUSETTS EYE & EAR INFIRMARY	W81XWH-17-1-0644		\$732	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF ALABAMA AT BIRMINGHAM	W81XWH-17-2-0037		\$34,445	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF PITTSBURGH	W81XWH-17-2-0073		\$17,012	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0074				\$58,086	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0345				\$33,226	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0563				\$636,853	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0564				\$588,729	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MINNESOTA	W81XWH-18-1-0577		\$4,792	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0650				\$128,252	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0652				\$15,850	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0676				\$116,203	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0760			\$191,740	\$308,549	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0021				\$219,204	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0029				\$443,033	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0081				\$25,540	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CONTRAFACT CORPORATION	W81XWH-19-1-0139		\$178,919	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0193				\$527	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		MD ANDERSON CANCER CENTER	W81XWH-19-1-0491		\$36,763	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534			\$508,976	\$1,250,108	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0583				\$690,775	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0680				\$77,959	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF CALIFORNIA DAVIS	W81XWH-19-1-0727		\$2,137	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0756				\$28,393	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		WASHINGTON UNIVERSITY	W81XWH-19-2-0042		\$47,971	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0214				\$230,486	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0215				\$169,250	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0262			\$118,616	\$403,825	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0322				\$139,442	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0400				\$692,311	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MARYLAND	W81XWH-20-1-0432		\$39,119	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		HOUSTON METHODIST RESEARCH	W81XWH-20-1-0600		\$13,919	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0662				\$101,246	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MINNESOTA	W81XWH-20-1-0682		\$186,837	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0752				\$192,446	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0886				\$187,178	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0903				\$194,366	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0923			\$206,290	\$512,179	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		WASHINGTON UNIVERSITY	W81XWH-20-9-0021		\$43,950	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		TREADMETRIX	W81XWH-20-C-0104		\$115,808	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0063				\$181,466	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0082				\$100,128	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0182			\$106,263	\$400,835	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MELBOURNE	W81XWH-21-1-0401		\$13,767	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0405				\$137,606	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0428				\$175,118	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0475				\$418,226	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF PITTSBURGH MEDICAL CENTER	W81XWH-21-1-0480		\$484,504	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0489				\$248,825	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0490				\$506,989	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0624				\$300,775	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF ALABAMA AT BIRMINGHAM	W81XWH-21-1-0665		\$331,410	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0678				\$230,653	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0704				\$375,981	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0705				\$42,409	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0706				\$44,307	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MINNESOTA	W81XWH-21-1-0726		\$19,163	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0798				\$303,020	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0867				\$307,766	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0888				\$130,620	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0036				\$250,656	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF PITTSBURGH	W81XWH-21-9-0014		\$56,944	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0021				\$124,848	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0245				\$250,091	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0288				\$152,318	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0289				\$55,616	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0313				\$189,949	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0634				\$7,893	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0670				\$6,234	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0917				\$117,951	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0968				\$83,189	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0969				\$13,853	\$16,777,494	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		LUNA INNOVATIONS INCORPORATED	140D0422C0053		\$5,157	\$75,813	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		UNIVERSITY OF OXFORD	HR0011-20-2-0028		\$70,656	\$75,813	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		INTERNATIONAL CONSULTING ASSOCIATION	75F40120C00093		\$89,433	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		MITRE CORPORATION	75FCMC18D0047	\$261,216	\$1,260,626	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		UNIVERSITY OF GEORGIA	75N93019C00052		\$50,990	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		CRESTONE, INC.	75N93019C00056		\$10,483	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		BATTELLE MEMORIAL INSTITUTE	DE-AC05-76RL01830		\$8,117	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC	FA8650-19-C-6979			\$74,067	\$725,647	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC	H98230-13-D-0123				\$888,615	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC	H98230-18-D-0024			\$60,000	\$3,704,857	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC	H98230-22-C-0095				\$946,877	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC	MTEC 2020-625				\$2,909,910	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		UNIVERSITY OF FLORIDA	UF-WAR53		\$16,596	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		UNIVERSITY OF PITTSBURGH	W81XWH-15-9-001		\$379,646	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		THE GENEVA FOUNDATION	W81XWH-17-C-0029		\$81,423	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		THE GENEVA FOUNDATION	W81XWH-17-C-0253		\$285	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		SOUTHWEST AUTISM RESEARCH & RESOURCE CENTER	W81XWH-20-1-0171		\$33,235	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		UNIVERSITY OF NEW MEXICO	W81XWH-20-1-0930		\$31,283	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		ENGINEERING & COMPUTER SIMULATIONS, INC.	W81XWH-20-C-0013		\$41,341	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RDC		VIVONICS, INC.	W81XWH-21-C-0025		\$100,170	\$11,279,534	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	12.RND		UNIVERSITY OF NEBRASKA MEDICAL CENTER	F-2020-102		\$21,585	\$21,585	RESEARCH AND DEVELOPMENT	\$425,554,624
TOTAL DEPARTMENT OF DEFENSE						\$2,431,701	\$33,935,139		

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT									
SUPPORTIVE HOUSING FOR THE ELDERLY	14.157	SUPPORTIVE HOUSING FOR THE ELDERLY				\$460,426	\$460,426	N/A	\$0
SECTION 8 HOUSING CHOICE VOUCHERS	14.871	SECTION 8 HOUSING CHOICE VOUCHERS				\$187,392	\$187,392	HOUSING VOUCHER CLUSTER	\$187,392
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT						<u>\$647,818</u>			
DEPARTMENT OF JUSTICE									
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2020-75-CX-0015				\$219,911	\$219,911	RESEARCH AND DEVELOPMENT	\$425,554,624
CRIME VICTIM ASSISTANCE	16.575					\$115,942	\$115,942	N/A	\$0
TOTAL DEPARTMENT OF JUSTICE						<u>\$335,853</u>			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
SCIENCE	43.001	80NSSC20K1139				\$21,823	\$339,882	RESEARCH AND DEVELOPMENT	\$425,554,624
SCIENCE	43.001	80NSSC21K0299				\$287,055	\$339,882	RESEARCH AND DEVELOPMENT	\$425,554,624
SCIENCE	43.001		KBR WYLE SERVICES, LLC	NNJK15HK11B		\$31,004	\$339,882	RESEARCH AND DEVELOPMENT	\$425,554,624
EXPLORATION	43.003	80NSSC21K0175				\$95,109	\$95,109	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	43.RDC	80JSC019P0041				\$8,631	\$8,631	RESEARCH AND DEVELOPMENT	\$425,554,624
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						<u>\$443,622</u>			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041		ODONATA MEDICAL	NSF 2026152		\$37,075	\$79,179	RESEARCH AND DEVELOPMENT	\$425,554,624
ENGINEERING	47.041		SEQUITUR HEALTH CORPORATION	NSF 2111884		\$10,547	\$79,179	RESEARCH AND DEVELOPMENT	\$425,554,624
ENGINEERING	47.041		NATIONAL SCIENCE FOUNDATION	NSF 2122901		\$35	\$79,179	RESEARCH AND DEVELOPMENT	\$425,554,624
ENGINEERING	47.041		FRONTIER BIO CORPORATION	NSF 2127127		\$31,522	\$79,179	RESEARCH AND DEVELOPMENT	\$425,554,624
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		GEORGIA INSTITUTE OF TECHNOLOGY	NSF #9		\$77,153	\$129,272	RESEARCH AND DEVELOPMENT	\$425,554,624
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		UNIVERSITY OF NORTH FLORIDA	NSF 2108060		\$23,518	\$129,272	RESEARCH AND DEVELOPMENT	\$425,554,624
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 2113360				\$28,601	\$129,272	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1624615			\$16,564	\$72,964	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1837572				\$3,734	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		PURDUE UNIVERSITY	NSF 1901046		\$22,588	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	NSF 2002540		\$7,536	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2041339				\$208,027	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2123900				\$207,698	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		OXALO THERAPEUTICS, INC.	NSF 2200058		\$49,308	\$571,855	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOLOGICAL SCIENCES	47.074		IOWA STATE UNIVERSITY	NSF 23494		\$64,069	\$64,069	RESEARCH AND DEVELOPMENT	\$425,554,624
STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES)	47.076	NSF-GRFP19				\$39,669	\$79,897	RESEARCH AND DEVELOPMENT	\$425,554,624
STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES)	47.076	NSF-GRFP21				\$37,119	\$79,897	RESEARCH AND DEVELOPMENT	\$425,554,624
STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES)	47.076		ARIZONA STATE UNIVERSITY	NSF 2152254		\$1,793	\$79,897	RESEARCH AND DEVELOPMENT	\$425,554,624
STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES)	47.076		ST. CATHERINE UNIVERSITY	NSF 2216826		\$1,316	\$79,897	RESEARCH AND DEVELOPMENT	\$425,554,624
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079		UNIVERSITY OF WISCONSIN MADISON	OISE-20-66590		\$23,850	\$31,913	RESEARCH AND DEVELOPMENT	\$425,554,624
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079		CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-9531011		\$8,063	\$31,913	RESEARCH AND DEVELOPMENT	\$425,554,624
TOTAL NATIONAL SCIENCE FOUNDATION					\$16,564	<u>\$956,185</u>			
DEPARTMENT OF VETERANS AFFAIRS									
CONTRACT	64.RD	IPA AGREEMENT-MORROW				\$5,228	\$90,779	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	64.RD	IPA AGREEMENT-PERSAD				\$85,551	\$90,779	RESEARCH AND DEVELOPMENT	\$425,554,624
TOTAL DEPARTMENT OF VETERANS AFFAIRS						<u>\$90,779</u>			

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF EDUCATION									
FEDERAL PELL GRANT PROGRAM	84.063					\$13,537	\$13,537	STUDENT FINANCIAL ASSISTANCE	\$16,350,962
FEDERAL DIRECT STUDENT LOANS	84.268					\$16,337,425	\$16,337,425	STUDENT FINANCIAL ASSISTANCE	\$16,350,962
TOTAL DEPARTMENT OF EDUCATION									
						\$16,350,962			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION	93.068	DP06703				\$260,041	\$260,041	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080		GREAT LAKES HEMOPHILIA FOUNDATION	NU27DD000020		\$27,068	\$27,068	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		HARVARD PILGRIM HEALTH CARE	75F40119D10037		\$23,561	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
			UNIVERSITY OF MISSOURI - KANSAS						
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		CITY	75F40122C00183		\$580	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		ARIZONA STATE UNIVERSITY	FD006102		-\$44,902	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD006102				\$93,764	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		SOCIETY CRITICAL CARE MEDICINE	FD05320		\$170,034	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		YALE UNIVERSITY	FD05938	\$121,859	\$1,453,302	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD06102				\$259,139	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		MEDICAL DEVICE INNOVATION	FD06292	\$333,163	\$530,513	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
			CINCINNATI CHILDREN'S HOSPITAL						
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		MEDICAL CENTER	FD07267		\$4,373	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD07288				\$39	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD07290			\$61,959	\$648,394	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD07472				\$171,564	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD7288				\$108,013	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103		UNIVERSITY OF MINNESOTA	FD7483		\$8,390	\$3,426,764	RESEARCH AND DEVELOPMENT	\$425,554,624
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		GREAT LAKES HEMOPHILIA FOUNDATION	MC24052		\$39,588	\$39,588	RESEARCH AND DEVELOPMENT	\$425,554,624
ENVIRONMENTAL HEALTH	93.113		UNIVERSITY OF MICHIGAN	ES31549		\$374	\$181,245	RESEARCH AND DEVELOPMENT	\$425,554,624
			FLORIDA INTERNATIONAL UNIVERSITY						
ENVIRONMENTAL HEALTH	93.113			ES33892		\$180,871	\$181,245	RESEARCH AND DEVELOPMENT	\$425,554,624
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE031424				\$34,455	\$405,826	RESEARCH AND DEVELOPMENT	\$425,554,624
ORAL DISEASES AND DISORDERS RESEARCH	93.121		UNIVERSITY OF NEW MEXICO	DE28096		\$24,161	\$405,826	RESEARCH AND DEVELOPMENT	\$425,554,624
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE28105			\$4,733	\$296,538	\$405,826	RESEARCH AND DEVELOPMENT	\$425,554,624
ORAL DISEASES AND DISORDERS RESEARCH	93.121		UNIVERSITY OF NORTH CAROLINA	DE29754		\$50,672	\$405,826	RESEARCH AND DEVELOPMENT	\$425,554,624
GRANTS TO INCREASE ORGAN DONATIONS	93.134		ARBOR RESEARCH COLLABORATIVE	EHS32756		\$26,040	\$55,630	RESEARCH AND DEVELOPMENT	\$425,554,624
			UNIVERSITY OF KANSAS MEDICAL CENTER						
GRANTS TO INCREASE ORGAN DONATIONS	93.134			HS33878		\$29,590	\$55,630	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172	HG06379			\$184,942	\$1,295,815	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172		BRIGHAM AND WOMENS HOSPITAL	HG06834		\$135,375	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172	HG09542				\$124,702	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172		UNIVERSITY OF NORTH CAROLINA	HG09650		\$94,386	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172		CASE WESTERN RESERVE UNIVERSITY	HG09668		\$65,556	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172	HG11461				\$19,244	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172	HG11662			\$88,356	\$185,107	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172	HG11710				\$679,893	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172	HG11899				\$356,152	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
HUMAN GENOME RESEARCH	93.172		UNIVERSITY OF NORTH CAROLINA	HG12402		\$31,531	\$2,987,761	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC012519				\$11,508	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC019564				\$702	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC12519				\$549,705	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		UNIVERSITY OF CALIFORNIA LOS ANGELES	DC13256		\$7,361	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC14942				\$255,808	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		OHIO STATE UNIVERSITY	DC18920		\$63,393	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19114			\$12,665	\$408,659	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		ARIZONA STATE UNIVERSITY	DC19475		\$32,640	\$1,329,776	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		IMMUNOGEN X	AI134590		\$29,209	\$599,703	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010875				\$300,136	\$599,703	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		MINNESOTA HEALTHSOLUTIONS CORPORATION	AT09665		\$172,302	\$599,703	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		NEW YORK SCHOOL OF MEDICINE	AT09844		\$32,776	\$599,703	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12185				\$65,280	\$599,703	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	75Q80120000005				\$273,494	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS028475				\$52,263	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF MINNESOTA	HS25164		\$16,734	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25402				\$51,040	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		VIRGINIA COMMONWEALTH UNIVERSITY	HS25412		\$100,120	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF WISCONSIN MADISON	HS25713		\$10,575	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF MINNESOTA	HS26379		\$209,923	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26609			\$41,266	\$304,726	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28060				\$77,671	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28639				\$32,297	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		SOCIETY FOR ACADEMIC EMERGENCY	HS28770		\$3,981	\$1,132,824	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134808				\$396,832	\$1,147,378	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134885				\$526,300	\$1,147,378	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		INNOVATIVE DESIGN LABS INC.	HL152948		\$29,505	\$1,147,378	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160619				\$50,787	\$1,147,378	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		MINNESOTA HEALTHSOLUTIONS CORPORATION	HL162131		\$1,252	\$1,147,378	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL65176				\$142,702	\$1,147,378	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131254				\$8,708	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242		MINNESOTA HEALTHSOLUTIONS CORPORATION	MH109190		\$57,020	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	MH109648		\$23,224	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242	MH113700			\$160,622	\$344,653	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	MH114967		\$148,746	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242		HARVARD SCHOOL OF PUBLIC HEALTH	MH121191		\$107,092	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121924				\$386,443	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242	MH122258			\$61,653	\$332,918	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124655			\$11,140	\$444,956	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF WASHINGTON	MH125935		\$43,793	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	MH129301		\$98,952	\$1,996,505	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF NEBRASKA	AA20735		\$240,120	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA21171				\$450,742	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA21788				\$255,984	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA26886				\$40,196	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA26887				\$507,593	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA26974				\$300,739	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA27179			\$168,505	\$391,214	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA27486				\$509,477	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA27487			\$157,948	\$514,240	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA28050				\$128,272	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA28968				\$211,486	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA29258				\$325,811	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
ALCOHOL RESEARCH PROGRAMS	93.273	AA30587				\$16,734	\$3,892,608	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		NYU LANGONE MEDICAL CENTER	CA261067		\$10,066	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	CA278594				\$14,539	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		HENNEPIN HEALTHCARE RESEARCH	DA40316		\$90,437	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA42492				\$1,035,550	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA46008			\$24,347	\$70,987	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		YALE UNIVERSITY	DA47003		\$155,969	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WASHINGTON UNIVERSITY	DA54725		\$3,737	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55848				\$62,073	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA56469			\$13,496	\$101,936	\$1,545,294	RESEARCH AND DEVELOPMENT	\$425,554,624
CENTERS FOR DISEASE CONTROL AND PREVENTION INVESTIGATIONS AND TECHNICAL ASSISTANCE	93.283	DP06491				\$692,494	\$692,494	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB001981				\$432,055	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB017095				\$32,771	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB032958				\$6,176	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17095				\$456,318	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17197				\$203,810	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		THE RESEARCH FOUNDATION FOR SUNY	EB17270		\$6,943	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19403				\$523,448	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24403				\$22,582	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24450			\$459,750	\$891,964	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF SOUTHERN CALIFORNIA	EB26284		\$56,249	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26780			\$35,619	\$176,160	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		GE CAPITAL	EB26976		\$146,499	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27064				\$405,012	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		STANFORD UNIVERSITY	EB27100		\$27,459	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27742				\$48,597	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28590				\$600,378	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28591				\$312,527	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28936				\$277,529	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB30529			\$166,766	\$755,274	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31790				\$248,739	\$5,630,490	RESEARCH AND DEVELOPMENT	\$425,554,624
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	68337101				\$10,000	\$353,400	N/A	\$0
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	435400-A21				\$257,696	\$353,400	N/A	\$0
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	NH23IP922611				\$85,704	\$353,400	N/A	\$0
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		NORTHERN ARIZONA UNIVERSITY	MD012388		\$162	\$1,332,410	RESEARCH AND DEVELOPMENT	\$425,554,624
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD09682			\$3,603	\$81,516	\$1,332,410	RESEARCH AND DEVELOPMENT	\$425,554,624
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		MEDICAL COLLEGE OF WISCONSIN	MD10728		\$7,149	\$1,332,410	RESEARCH AND DEVELOPMENT	\$425,554,624
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD16230				\$155,442	\$1,332,410	RESEARCH AND DEVELOPMENT	\$425,554,624
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17217				\$11,771	\$1,332,410	RESEARCH AND DEVELOPMENT	\$425,554,624
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		UNIVERSITY OF MINNESOTA	MD17342		\$1,076,370	\$1,332,410	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310		UNIVERSITY OF MINNESOTA	AG79754		\$14,651	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	A1142773				\$324,972	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	CA220378				\$192,050	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	CA243545				\$23,408	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310		UNIVERSITY OF MICHIGAN	CA268091		\$18,258	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	CA268103				\$518,787	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	CA272883				\$33,457	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	DK112326				\$1,606,878	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310		UNIVERSITY OF TEXAS AT EL PASO	GM118971		\$7,605	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310		MEDICAL COLLEGE OF WISCONSIN	HG10423		\$97,805	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	NS105853				\$260,874	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310		CONWAY MEDICAL, LLC	NS122602		\$36,668	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	OD034496				\$14,121	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	OD23121				\$25,542,884	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANS-NIH RESEARCH SUPPORT	93.310	TR02471				\$612,862	\$29,305,280	RESEARCH AND DEVELOPMENT	\$425,554,624
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318		VANDERBILT UNIVERSITY MEDICAL CENTER	NU3HCK000006		\$624	\$624	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		UNIVERSITY OF COLORADO	TR002306		\$175,493	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002377				\$6,156,241	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002379				\$1,311,088	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02062			\$963,378	\$1,252,794	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02380				\$541,408	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02743			\$628,113	\$1,428,285	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR03174				\$8,706	\$10,874,015	RESEARCH AND DEVELOPMENT	\$425,554,624
RESEARCH INFRASTRUCTURE PROGRAMS	93.351		IOWA STATE UNIVERSITY	OD20166		\$320,374	\$320,374	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA15083				\$21,317	\$3,785,087	RESEARCH AND DEVELOPMENT	\$425,554,624
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA224018			\$231,414	\$867,649	\$3,785,087	RESEARCH AND DEVELOPMENT	\$425,554,624
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233033			\$69,905	\$1,898,511	\$3,785,087	RESEARCH AND DEVELOPMENT	\$425,554,624
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		UNIVERSITY OF NORTH CAROLINA	CA233046		\$399,274	\$3,785,087	RESEARCH AND DEVELOPMENT	\$425,554,624
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA246568			\$51,851	\$598,336	\$3,785,087	RESEARCH AND DEVELOPMENT	\$425,554,624
PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE	93.354		MINNESOTA DEPARTMENT OF HEALTH	NU90TP92		\$10,696	\$10,696	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT	93.360		DUKE UNIVERSITY	HHS-O-100-2014-000021		\$54,695	\$54,695	RESEARCH AND DEVELOPMENT	\$425,554,624
NURSING RESEARCH	93.361	NR020362				\$78,396	\$952,668	RESEARCH AND DEVELOPMENT	\$425,554,624
NURSING RESEARCH	93.361	NR15441			\$2,149	\$10,434	\$952,668	RESEARCH AND DEVELOPMENT	\$425,554,624
NURSING RESEARCH	93.361	NR16433			\$19,068	\$221,532	\$952,668	RESEARCH AND DEVELOPMENT	\$425,554,624
NURSING RESEARCH	93.361	NR18832				\$565,369	\$952,668	RESEARCH AND DEVELOPMENT	\$425,554,624
NURSING RESEARCH	93.361	NR20362			\$11,191	\$76,937	\$952,668	RESEARCH AND DEVELOPMENT	\$425,554,624
21ST CENTURY CURES ACT - PRECISION MEDICINE INITIATIVE	93.368	OD23121				\$4,179	\$4,179	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF MINNESOTA	CA142714		\$2,149	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		STANFORD UNIVERSITY	CA167551		\$285,500	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA195568			\$818,636	\$2,023,368	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207084			\$118,153	\$225,182	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA207360		\$10,263	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF MASSACHUSETTS	CA207369		\$108,287	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA208517				\$86,746	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA213645			\$99,577	\$131,622	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA214225			\$14,274	\$48,101	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217183				\$327,613	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217889				\$364,188	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	CA222253		\$31,182	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF VIRGINIA	CA224293		\$119,499	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224917			\$35,192	\$336,653	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225662				\$197,699	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA230712				\$774,174	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		KAISER FOUNDATION RESEARCH INSTITUTE	CA233432		\$47,323	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233522			\$13,385	\$13,385	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233610				\$708,481	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233700				\$403,515	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA234943				\$106,717	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235026				\$653,700	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237398				\$274,432	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237607			\$87,242	\$808,921	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		BAYLOR COLLEGE OF MEDICINE	CA243483		\$49,201	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF WASHINGTON	CA244670		\$154,094	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		ST. JUDE CHILDREN'S HOSPITAL	CA246510		\$38,642	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		JOHNS HOPKINS UNIVERSITY	CA247283		\$25,433	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		ALASKA NATIVE TRIBAL HEALTH CONSORTIUM	CA247642		\$5,416	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA248288			\$304,788	\$790,832	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253187				\$715,815	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		CARINA MEDICAL, LLC	CA254844		\$136	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254951				\$746,609	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF WASHINGTON	CA255082		\$8,942	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		WASHINGTON UNIVERSITY	CA256810		\$6,197	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258058				\$14,331	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF VERMONT	CA258119		\$1,772	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA259201				\$280,601	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF WISCONSIN MADISON	CA26211		\$8,987	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		TUFTS MEDICAL CENTER, INC.	CA262265		\$46,452	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262393			\$8,531	\$236,086	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA264600				\$466,186	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265018				\$30,000	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265019				\$15,000	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265050				\$331,524	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	CA265967		\$18,371	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269264				\$27,010	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA271014			\$2,798	\$285,284	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272473				\$92,853	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA277825				\$48,222	\$12,532,696	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA116161				\$55,255	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF PENNSYLVANIA	CA161749		\$25,129	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168575				\$38,676	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168762				\$217,079	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		PARTNERS HEALTH CARE RES MGMT	CA184102		\$132	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		DANA-FARBER CANCER INSTITUTE	CA186709		\$218	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA195527			\$3,615	\$54,620	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		WASHINGTON UNIVERSITY	CA196171		\$586,377	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA204013				\$70,276	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA206584				\$315,318	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210138			\$126,383	\$561,753	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210509				\$39,917	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA212162			\$31,118	\$593,227	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ST. JOSEPH HOSPITAL	CA213158		\$48,214	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		FRED HUTCHINSON CANCER RESEARCH CENTER	CA214114		\$13,648	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		BAYLOR RESEARCH INSTITUTE	CA214125		\$6,132	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214679				\$323,709	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA216855			\$193,144	\$475,788	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA217847				\$193,716	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	CA218429		\$14,092	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ST. JOSEPH HOSPITAL	CA221938		\$3,545	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF WISCONSIN MADISON	CA223481		\$8,546	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA229811			\$45,647	\$827,504	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA234827				\$33,929	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA236612				\$156,991	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237602			\$146,292	\$658,451	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF TEXAS						
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		SOUTHWESTERN MEDICAL CENTER	CA237659		\$78,901	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239164				\$335,108	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239200			\$399,970	\$918,043	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239548				\$469,747	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		PURDUE UNIVERSITY	CA240181		\$227,898	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241020				\$35,311	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241164			\$92,243	\$569,374	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA244167				\$143,728	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF CENTRAL FLORIDA	CA246704		\$11,671	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ST. JOSEPH HOSPITAL	CA247606		\$84,549	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251065				\$383,514	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251801			\$234,222	\$726,314	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251923				\$126,946	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		MD ANDERSON CANCER CENTER	CA252156		\$52,326	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256648				\$139,506	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA256969		\$364,292	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA257558			\$289,583	\$670,159	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA258465				\$40,364	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA260259				\$108,364	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		WASHINGTON UNIVERSITY	CA271402		\$1,883	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271410				\$165,715	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA272628				\$14,343	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA274496				\$118,257	\$11,108,555	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		DANA-FARBER CANCER INSTITUTE	CA186709		\$302,325	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA232760				\$957,292	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		WESTAT	75N91021C00012		\$13,995	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	A191401	MOUNT SINAI MEDICAL CENTER OF FLORIDA	CA108671		\$890	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA150190				\$535,253	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA179157				\$134,057	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA180882	DUKE CLINICAL RESEARCH INSTITUTE	CA180790		\$47,690	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$86,241	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$383,884	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		BRIGHAM AND WOMENS HOSPITAL	CA180821		\$422,817	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$626,868	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$10,329,865	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		THE CHILDRENS HOSPITAL OF PHILADELPHIA	CA180886		\$20,380	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$10,434	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$10,434	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA181255		\$472,277	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA186686				\$136,161	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$198,435	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		DANA-FARBER CANCER INSTITUTE	CA186709		\$65,206	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA189823				\$2,781	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA190423				\$4,070	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA195473	MODULATION THERAPEUTICS	CA195946		\$53,730	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$70,138	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA200507				\$148,001	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		PPD DEVELOPMENT	CA203430		\$227,655	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$17,712	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA207183				\$148,792	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA207240	DANA-FARBER CANCER INSTITUTE	CA205406		\$352,546	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA207386				\$40,110	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$96,701	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA211887	CEDARS SINAI MEDICAL CENTER	CA208851		\$198,547	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$16,693	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$75,292	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF CHICAGO	CA216436		\$158,988	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$73,855	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$452,902	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA219960	SYNTRIX BIOSYSTEMS, INC.	CA217591		\$21,818	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$21,818	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$1,753	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA225996	VETERANS MEDICAL RESEARCH FOUNDATION	CA222866		\$466,692	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA227954				\$210,931	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$39,898	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA229100	THE CHILDRENS HOSPITAL OF PHILADELPHIA	CA228823		\$1,813,204	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA229560				\$250,781	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$41,515	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		DUKE UNIVERSITY	CA232760		\$59,860	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$52,737	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$72,017	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		SLOAN-KETTERING CANCER RESEARCH	CA233332		\$35,880	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$6,382	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA243078				\$408,480	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA248064	NORTHWESTERN UNIVERSITY	CA233878		\$528,028	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA248147				\$18,175	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$104,936	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF PENNSYLVANIA	CA249929		\$3,566	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA25224				\$71,537	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395					\$512,310	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA256927	SANFORD-BURNHAM MEDICAL	CA251910		\$367,120	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA257241				\$367,702	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA258239				\$169,011	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA259236	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	CA243078		\$316,815	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA261854				\$70,706	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA262994				\$84,987	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA263003	UNIVERSITY OF LOUISIANA AT MONROE	CA255176		\$335,306	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA264362				\$512,035	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA266344				\$1,178	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA266999				\$1,178	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	CA267098				\$51,974	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		IOWA STATE UNIVERSITY	CA267372		\$16,437	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		OLEOLIVE, LLC	CA268286		\$40,999	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA272257			\$10,853	\$74,587	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA274985				\$20,699	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395		TARGEPEUTICS	CA275560		\$11,783	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA37404				\$531	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	CA78383				\$9,570	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER TREATMENT RESEARCH	93.395	ECOG1412				\$3,652	\$24,727,826	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA130908				\$206,649	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER	CA194215		\$119,770	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA196831				\$18,477	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA203849				\$162,315	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		BOSTON UNIVERSITY	CA214292		\$59,559	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA214893				\$162,906	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		MDI BIOLOGICAL LABORATORY	CA215973		\$1,840	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA217833				\$481,228	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA220378			\$76,135	\$540,709	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA224921				\$319,398	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA225680				\$333,469	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA233790				\$572,303	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA234181				\$294,617	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		MASSACHUSETTS INSTITUTE OF TECHNOLOGY	CA238720		\$36,129	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA239726				\$286,040	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA240323				\$352,358	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY AT BUFFALO	CA241123		\$74,529	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA242023				\$271,058	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA243545				\$371,620	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA247929				\$313,624	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF MINNESOTA	CA248019		\$16,632	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA249116				\$499,136	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA250481			\$168,941	\$741,041	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF SOUTH WALES	CA251443		\$6,898	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF MINNESOTA	75F40120C00093		\$11,998	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA254961				\$432,349	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA255068				\$198,492	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	CA256481		\$70,705	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA258274				\$177,937	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA261925				\$336,169	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA261932				\$360,723	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA264048			\$46,939	\$534,043	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396		JOAN & SANFORD I. WEILL MEDICAL COLLEGE	CA265892		\$20,591	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA266113				\$19,049	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA271486			\$33,897	\$273,784	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA275669				\$113,640	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA81436				\$513,654	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER BIOLOGY RESEARCH	93.396	CA96985				\$271,331	\$9,576,770	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083				\$5,998	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397	CA116201			\$23,068	\$1,228,446	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397	CA136393			\$370,806	\$1,987,092	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083			\$4,728	\$6,786,333	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	CA163004		\$57,783	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		CASE WESTERN RESERVE UNIVERSITY	CA163060		\$17,132	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		DANA-FARBER CANCER INSTITUTE	CA168504		\$11,443	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397	CA186781			\$98,280	\$1,777,830	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		BAYLOR COLLEGE OF MEDICINE MASSACHUSETTS INSTITUTE OF TECHNOLOGY	CA186784		\$8,383	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		METHUEN HOSPITAL RESEARCH	CA210180		\$54,448	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		UNIVERSITY OF MINNESOTA	CA210190		\$572	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397					\$38,010	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CENTERS SUPPORT GRANTS	93.397	CA210964			\$436,589	\$2,257,519	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		NORTHWESTERN UNIVERSITY	CA221205		\$241	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		UNIVERSITY OF FLORIDA	CA233444		\$23,554	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CENTERS SUPPORT GRANTS	93.397		UNIVERSITY OF IOWA	CA97274	\$6,726	\$1,585,998	\$15,840,782	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA250122				\$51,872	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA250326				\$49,276	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA257228				\$46,659	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA210964				\$106,462	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA213737				\$1,804	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA214225			\$18,835	\$119,154	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA215105				\$94,219	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA217836				\$182,919	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA225786				\$73,747	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA230193				\$23,420	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA235848				\$54,140	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA236874				\$258,811	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA237875				\$173,420	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398		UNIVERSITY OF FLORIDA	CA248972		\$12,509	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA271560				\$32,366	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA273304				\$29,308	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER RESEARCH MANPOWER	93.398	CA90628				\$769,839	\$2,079,925	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CONTROL	93.399		OHIO STATE UNIVERSITY	CA189823		\$2,053,001	\$2,618,598	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CONTROL	93.399		THE CHILDRENS HOSPITAL OF PHILADELPHIA	CA189955		\$2,317	\$2,618,598	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CONTROL	93.399	CA220242				\$542,084	\$2,618,598	RESEARCH AND DEVELOPMENT	\$425,554,624
CANCER CONTROL	93.399		UNIVERSITY OF WISCONSIN MADISON	CA242635		\$21,196	\$2,618,598	RESEARCH AND DEVELOPMENT	\$425,554,624
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433		INDIANA UNIVERSITY	90DPHF0006		\$4,085	\$503,701	RESEARCH AND DEVELOPMENT	\$425,554,624
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0012				\$326,133	\$503,701	RESEARCH AND DEVELOPMENT	\$425,554,624
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433		CRAIG HOSPITAL	90DPTB0017		\$12,313	\$503,701	RESEARCH AND DEVELOPMENT	\$425,554,624
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0031				\$118,385	\$503,701	RESEARCH AND DEVELOPMENT	\$425,554,624
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433		UNIVERSITY OF MINNESOTA	90SIMS0008		\$42,785	\$503,701	RESEARCH AND DEVELOPMENT	\$425,554,624
COVID-19 HRSA COVID-19 CLAIMS REIMBURSEMENT FOR THE UNINSURED PROGRAM AND THE COVID-19 COVERAGE ASSISTANCE FUND	93.461	COVID-19				\$2,379,997	\$2,379,997	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF CALIFORNIA BERKELEY	HL115153		\$75,346	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		SOCIAL AND SCIENTIFIC SYSTEMS	CR8-SSS-S-21-006050		\$128,403	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL07111				\$444,521	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107304			\$15,428	\$427,833	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117823			\$56,819	\$330,938	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117913				\$344,884	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL119795				\$43,986	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		OKLAHOMA MEDICAL RESEARCH FOUNDATION	HL120877		\$7,375	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128526				\$52,220	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		VANDERBILT UNIVERSITY MEDICAL CENTER	HL129941		\$268,672	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	HL130163		\$8,836	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL131535				\$55,614	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL132854				\$82,868	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL133501			\$431,368	\$559,930	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134664				\$90,977	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134668				\$153,671	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134864				\$339,995	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF PENNSYLVANIA	HL134905		\$12,118	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	HL135165		\$3,058	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135879				\$226,640	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136340				\$296,867	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136348				\$334,379	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136440				\$455,210	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136659	UNIVERSITY OF MINNESOTA	HL136679		\$367,487	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837					\$2,437	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137010				\$120,866	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140411			\$5,065	\$89,957	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140951			\$55,814	\$384,182	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141819				\$27,005	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142068				\$350,875	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142627				\$406,093	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		MASSACHUSETTS GENERAL HOSPITAL	HL143070		\$7,165	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL144529			\$178,129	\$922,794	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145121				\$192,491	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145268			\$387,501	\$834,284	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF CHICAGO	HL146127		\$19,062	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837					\$5,364	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147155	UNIVERSITY OF MICHIGAN	HL146619		\$647,332	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		VERSITI	HL148120		\$8,233	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148144				\$148,618	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148339				\$341,912	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	HL148664		\$233,724	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL150086				\$380,242	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		NORTHWESTERN UNIVERSITY	HL151079		\$33,156	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL153098				\$392,646	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155040				\$36,828	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		NORTH CAROLINA STATE UNIVERSITY	HL155373		\$67,548	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837					\$36,412	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156855	UNIVERSITY OF MICHIGAN	HL155834		\$75,881	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158517				\$418,648	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158548			\$49,685	\$207,657	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158691				\$112,687	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158932				\$415,234	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		INDIANA UNIVERSITY	HL159216		\$3,290	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160226				\$242,970	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160643				\$64,277	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160761				\$402,106	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161169				\$726,568	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161272				\$43,066	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		BINGHAMTON UNIVERSITY	HL161765		\$3,751	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161821				\$95,260	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		VIVITA TECHNOLOGIES, INC.	HL164140		\$13,749	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164520				\$233,260	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165176			\$43,866	\$183,951	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL66216				\$13,058	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL81753				\$296,705	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84155				\$381,126	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL92621				\$76,887	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837		JOHNS HOPKINS UNIVERSITY	HL96812		\$233,075	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL98967				\$561,838	\$15,606,098	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL105355				\$489,865	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		VANDERBILT UNIVERSITY MEDICAL CENTER	HL108800		\$11,001	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838					\$61,435	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL126667	CLEVELAND CLINIC FOUNDATION	HL125177		\$636,809	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL127267			\$60,891	\$222,706	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL130881			\$106,466	\$421,485	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		PARTNERS HEALTH CARE RES MGMT	HL137366		\$1,035	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL138150			\$2,642	\$135,139	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF NORTH CAROLINA	HL138998		\$100,429	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838					\$50,453	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF ARIZONA	HL139054		\$8,325	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838								
LUNG DISEASES RESEARCH	93.838		INDIANA UNIVERSITY	HL139126					
LUNG DISEASES RESEARCH	93.838								
LUNG DISEASES RESEARCH	93.838		MASSACHUSETTS GENERAL HOSPITAL	HL140177		\$116,245	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL140486			\$126,206	\$729,763	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		STANFORD UNIVERSITY	HL141722		\$271,428	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838								

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	HL142061				\$587,307	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		BRIGHAM AND WOMENS HOSPITAL	HL142093		\$75,873	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF PENNSYLVANIA	HL142269		\$97,305	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		BOSTON UNIVERSITY	HL142596		\$28,314	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL142933			\$146,674	\$568,812	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL142992				\$406,468	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF MICHIGAN	HL145265	\$240,276	\$15,072	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL146114				\$762,784	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL146461				\$502,402	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		NORTH DAKOTA STATE UNIVERSITY	HL146705		\$187,337	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL146741				\$232,682	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF MICHIGAN	HL147261		\$8,271	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		NATIONAL JEWISH HEALTH	HL148437		\$19,582	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL151671				\$153,229	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF COLORADO	HL151865		\$9,824	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL152967			\$285,985	\$629,342	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL153026				\$643,584	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		STANFORD UNIVERSITY	HL155410		\$120,520	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		NATIONAL JEWISH HEALTH	HL157424		\$135,724	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL157984				\$787,580	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL158018				\$69,139	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL158532			\$30,177	\$278,958	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL158549				\$60,294	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL158811				\$107,839	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL160545				\$105,510	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838		NYU GROSSMAN SCHOOL OF MEDICINE	HL161847		\$9,421,159	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL166187				\$8,926	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL56470			\$31,429	\$182,253	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL62150				\$419,649	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL88029				\$656,202	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
LUNG DISEASES RESEARCH	93.838	HL92961			\$59,541	\$467,616	\$21,005,675	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		NATIONAL MARROW DONOR PROGRAM	BMT CTN 1506		\$9,386	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		FRED HUTCHINSON CANCER RESEARCH CENTER	HL126589		\$61,905	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		VERSITI	HL130724		\$15,359	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133479				\$32,267	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		DUKE CLINICAL RESEARCH INSTITUTE	HL133817		\$4,732	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL137193			\$100,733	\$362,235	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF ALABAMA	HL138645		\$17,915	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL139854				\$906,307	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CLEVELAND CLINIC FOUNDATION	HL140097		\$63,141	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL141112				\$210,818	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL146508				\$489,024	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147852				\$225,492	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF WASHINGTON	HL147894		\$47,885	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		VERSITI	HL148120		\$11,959	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL153310				\$162,606	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL154320				\$17,018	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF WASHINGTON	HL154385		\$61,861	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		OBSDIO, INC.	HL158397		\$125,560	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL159561				\$67,237	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		SANFORD-BURNHAM MEDICAL	HL161804		\$207,750	\$3,100,457	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL151662			\$256,779	\$733,667	\$1,099,036	RESEARCH AND DEVELOPMENT	\$425,554,624
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840		THE UNIVERSITY OF ARIZONA	HL158287		\$365,369	\$1,099,036	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR79842				\$23,115	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR056950				\$472,528	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR077538				\$114,957	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078552				\$33,924	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR27065				\$5,402	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR42527				\$276,854	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR46849				\$729,918	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR49069				\$192,707	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		BRIGHAM AND WOMENS HOSPITAL	AR55557		\$47,079	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55563			\$357,336	\$497,692	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56212				\$66,456	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56647				\$122,303	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56950	UNIVERSITY OF PENNSYLVANIA	AR57319		\$11,640	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$6,327	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR67707	EMMYON, INC.	AR69400		\$745	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$216,534	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR71338	UNIVERSITY OF MINNESOTA	AR71439	\$75,598	\$158,503	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$9,868	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR71762			\$64,902	\$129,125	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72597				\$120,224	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73147			\$32,730	\$420,436	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73811				\$276,704	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74228				\$24,948	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74395				\$321,766	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		NEUROMUSCULAR DYNAMICS, LLC	AR74859		\$2,475	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75037				\$515,660	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75370				\$10,198	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76028				\$26,597	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76312			\$74,547	\$885,971	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76339				\$382,264	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		INDIANA UNIVERSITY	AR76347		\$1,830	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76347				\$423,961	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		UNIVERSITY OF PITTSBURGH	AR76568		\$173,686	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77518				\$296,238	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		UNIVERSITY OF MICHIGAN	AR78073		\$20,707	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78254				\$142,341	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR79098			\$42,123	\$162,288	\$7,323,971	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123834				\$3,172	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$4,050	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127564				\$51,322	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128913				\$46,037	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$323,222	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MIAMI	APOL1		\$651	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07013				\$129,266	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07198				\$378,783	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07352				\$406,927	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	DK074008		\$13,401	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK078646				\$389,039	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF PENNSYLVANIA	DK100846		\$27,011	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$2,164	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		OASIS PHARMACEUTICALS, LLC	DK101240		\$6,350	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$28,074	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405	MEDICAL UNIVERSITY OF SOUTH CAROLINA	DK104833		\$133,200	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$31,365	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106667				\$82,129	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$2,752	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107255	SOUTHWESTERN MEDICAL CENTER	DK107733		\$124,794	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$200,218	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	DK108328		\$35,995	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288				\$570,881	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					\$18,533	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109134				\$65,693	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110024			\$22,776	\$93,982	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847								

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110136				\$123,529	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	DK110172		\$7,063	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DUKE UNIVERSITY	DK110988		\$213,392	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111378				\$567,658	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF KANSAS MEDICAL CENTER	DK113111		\$57,297	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113999			\$178,487	\$347,228	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114007				\$365,604	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114460				\$110,941	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114497				\$178,612	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	DK114857		\$10,667	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		GEORGIA REGENTS UNIVERSITY	DK115255		\$240,198	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115402				\$100,570	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF NORTH CAROLINA	DK115575		\$310,608	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115594				\$122,416	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOSLIN DIABETES CENTER	DK116102		\$1,258	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116231			\$15,000	\$639,638	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	DK116723		\$44,975	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MEDICAL UNIVERSITY OF SOUTH CAROLINA	DK116743		\$6,551	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		SANFORD-BURNHAM MEDICAL	DK117133		\$16,841	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117212			\$68,323	\$124,143	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MASSACHUSETTS GENERAL HOSPITAL	DK117236		\$21,917	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117861				\$319,404	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117910				\$303,240	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118120				\$186,516	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118391				\$69,333	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118619			\$319,677	\$702,312	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119167				\$363,389	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119646				\$569,436	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		OXALO THERAPEUTICS, INC.	DK120261		\$78,978	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120292				\$482,043	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		HARVARD UNIVERSITY	DK120358		\$46,646	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120559				\$261,890	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120745				\$26,828	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120808				\$102,271	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121204				\$218,972	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JAEB CENTER FOR HEALTH RESEARCH	DK121240		\$34,823	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF TEXAS HOUSTON	DK121330		\$39,831	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121766				\$351,816	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121888				\$199,038	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121943				\$184,920	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122187				\$64,066	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122280				\$391,448	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JAEB CENTER FOR HEALTH RESEARCH	DK122603		\$161,791	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122734				\$655,406	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122948				\$420,681	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123313				\$98,817	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		ARIZONA STATE UNIVERSITY	DK123441		\$83,590	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123492				\$103,795	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123549				\$320,699	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124182				\$387,124	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$163,010	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124358				\$146,563	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		ADVA-TEC, INS.	DK125243		\$55,482	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125252			\$249,256	\$642,558	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MINNESOTA	DK125431		\$463,725	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CEDARS SINAI MEDICAL CENTER	DK125495		\$83,144	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125632				\$100,928	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	DK125680		\$102,062	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ALABAMA	DK125692		\$12,089	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DUKE UNIVERSITY	DK125911		\$4,380	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126206			\$42,445	\$662,628	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126662				\$470,914	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126691				\$710,567	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126700				\$2,640	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126827				\$547,609	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127010				\$98,603	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF NORTH CAROLINA	DK127157		\$829	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CEDARS SINAI MEDICAL CENTER	DK127403		\$13,642	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127978				\$248,000	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127992				\$661,309	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127998				\$395,488	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128017				\$440,959	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF PITTSBURGH	DK128100		\$59,304	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128127				\$105,377	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128552				\$474,655	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF COLORADO	DK128842		\$26,754	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128844				\$433,083	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128987				\$42,628	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129208				\$134,726	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129240				\$98,055	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129241				\$377,872	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF COLORADO	DK129259		\$4,553	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129297				\$40,386	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129315			\$78,107	\$462,903	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		YALE UNIVERSITY	DK129616		\$24,364	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129708				\$66,241	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF COLORADO	DK129720		\$1,835	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129886				\$173,403	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129897				\$78,243	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130181				\$127,180	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130331				\$452,870	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130566			\$182,070	\$358,448	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130884				\$393,433	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	DK131133		\$307	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131455				\$292,922	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131685				\$367,289	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131946				\$110,844	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF NORTH CAROLINA	DK132001		\$10,681	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132121				\$27,079	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132651				\$220,709	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133171				\$123,404	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133897				\$6,422	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135097				\$54,084	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK24031				\$743,564	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF VIRGINIA	DK29953		\$38,062	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK40484				\$526,242	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44650				\$6,770	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK45343				\$532,301	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK52766				\$528,603	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57061				\$297,774	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		YALE UNIVERSITY	DK57846		\$5,279	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57993				\$297,823	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58185				\$19,381	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58816				\$454,348	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59597				\$467,756	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59615				\$214,151	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	DK74008		\$156,955	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78924				\$449,130	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	DK83912		\$105,353	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567				\$1,204,086	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF WISCONSIN MADISON	DK88925		\$45,859	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90358				\$546,711	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92255			\$37,153	\$597,849	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92460				\$550,595	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	DK94157		\$80,525	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98468				\$355,903	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99160				\$361,281	\$33,692,614	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115202				\$46,897	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS116924				\$29,080	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120605				\$45,777	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF TEXAS AT AUSTIN	NS062835		\$273,730	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS085070				\$348,901	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS092882				\$124,280	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS095869		\$46,409	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100620				\$1,301,120	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100693				\$543,853	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS100699		\$42,722	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS101721				\$256,361	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		TUFTS MEDICAL CENTER, INC.	NS102233		\$66,575	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS102289		\$12,877	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102360				\$318,752	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103212				\$396,203	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103870			\$566,780	\$955,422	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF SOUTHERN CALIFORNIA	NS104095		\$137,413	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CHICAGO	NS104157		\$102,206	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105853				\$185,446	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS106513		\$17,347	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		NEUROGAMI MEDICAL, INC.	NS107048		\$36,165	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		ANCURE LLC	NS107111		\$359,671	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107265				\$185,194	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107336				\$27,875	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		YALE UNIVERSITY	NS107624		\$19,902	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107946				\$62,913	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		HEALTH RESEARCH, INC.	NS108916		\$29,222	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109491				\$369,439	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110085				\$329,985	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		ENDOMIMETICS, LLC	NS110114		\$103,482	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS11043				\$56,684	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110435			\$1,498,034	\$3,331,518	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		COLUMBIA UNIVERSITY	NS110438		\$508,736	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS110728		\$3,652	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MARYLAND	NS110825		\$398,549	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110930				\$96,569	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110949				\$469,924	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110960			\$147,732	\$254,890	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110994				\$26,947	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUKE UNIVERSITY	NS111039		\$44,283	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		SANFORD-BURNHAM MEDICAL UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS111085		\$86,896	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853			NS111978		\$45,020	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CLEVELAND CLINIC FOUNDATION	NS111981		\$156,579	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144			\$18,423	\$457,757	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144A				\$237,379	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112153				\$466,146	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112176			\$88,400	\$396,744	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112339				\$207,067	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		YALE UNIVERSITY	NS112826		\$337,877	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113315			\$266,302	\$674,496	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIASAN FRANCISCO	NS113637		\$171,630	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		EVOGEN, INC.	NS113724		\$2,459	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113760				\$333,266	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113776				\$829,195	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113803				\$593,342	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113828				\$274,959	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		NORTHWESTERN UNIVERSITY	NS113851		\$1,529	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114147			\$197,640	\$430,508	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114365				\$60,472	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CHICAGO	NS114552		\$46,567	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115126				\$538,434	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198			\$676,637	\$1,610,632	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	NS115388	\$100,929	\$1,721,309	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF PITTSBURGH	NS115708		\$4,712	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115877				\$454,419	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CND LIFE SCIENCES	NS117214		\$700	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117432			\$88,227	\$437,219	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117461				\$289,656	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117799				\$162,285	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		OHIO STATE UNIVERSITY	NS117844		\$59,838	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118513			\$272,053	\$547,158	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		SUN HEALTH RESEARCH INSTITUTE	NS118669		\$67,824	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118790				\$152,360	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119169			\$105,537	\$340,216	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		HOUSTON METHODIST RESEARCH	NS119587		\$9,988	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		SCRIPPS RESEARCH INSTITUTE	NS119714		\$38,660	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		THE UNIVERSITY OF TEXAS HEALTH	NS119834		\$30,974	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		KEY TECHNOLOGIES INC.	NS119974		\$23,378	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		ST. JOSEPH HOSPITAL	NS120331		\$44,431	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF TEXAS SOUTHWEST MEDICAL CENTER	NS120496		\$34	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS120871		\$483	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120877				\$273,235	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF UTAH	NS120901		\$61,742	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120992			\$35,637	\$636,478	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121125				\$745,165	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CASE WESTERN RESERVE UNIVERSITY	NS121928		\$98,825	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122096				\$208,332	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122174				\$589,117	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		BINGHAMTON UNIVERSITY	NS122226		\$17,309	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		NEW YORK UNIVERSITY	NS122419		\$30,651	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		JOHNS HOPKINS UNIVERSITY	NS122764		\$14,134	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123052				\$215,576	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123066				\$106,778	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		STANFORD UNIVERSITY	NS123743		\$162,883	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF NEW MEXICO	NS123958		\$134,319	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MINNESOTA	NS124065		\$139,375	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124688				\$57,491	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125417			\$35,770	\$496,087	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MINNESOTA	NS125437		\$146,130	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		WINCS INTERNATIONAL, LLC	NS125895		\$36,059	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126227				\$322,388	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126417				\$65,398	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF PITTSBURGH	NS127187		\$44,890	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MEDICAL COLLEGE OF WISCONSIN	NS128199		\$28,552	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS31744			\$100,536	\$218,406	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS65705		\$9,761	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS73610			\$125,087	\$157,049	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		WASHINGTON UNIVERSITY	NS74969		\$448,041	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS76491			\$172,305	\$357,757	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168			\$2,837,795	\$4,636,584	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84974			\$1,162,490	\$1,744,245	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88260				\$6,321	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88627				\$285,931	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89757				\$805,053	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MIAMI	NS92091		\$162,017	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92625				\$674,342	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92882				\$77,692	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92891				\$146,160	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		BOSTON UNIVERSITY	NS93334		\$77,626	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS94124				\$286,789	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95495				\$652,433	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS95869		\$14,687	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CARNEGIE MELLON UNIVERSITY	NS96761		\$100,000	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97273				\$1,533,517	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97495				\$351,367	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CLEVELAND CLINIC FOUNDATION	NS97719		\$22,440	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		COLUMBIA UNIVERSITY	NS97876	\$73,641	\$160,345	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS99043		\$45,681	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	NS99043B		\$6,949	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		SCRIPPS RESEARCH INSTITUTE	NS99114		\$330,287	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS99268		\$121	\$42,254,084	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1132165				\$146,849	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1147438				\$16,991	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1170478				\$72,937	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A1104681		\$377,835	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CHICAGO	A1108682		\$46,531	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1108682				\$322,010	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1108891				\$311,367	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1108906				\$221,171	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	A1109565		\$122,553	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1110173				\$476,655	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A1110483		\$44,781	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF VIRGINIA	A1112844		\$12,795	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WASHINGTON UNIVERSITY	A1116501		\$7,694	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	A1117804		\$30,587	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1120698				\$298,415	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1120959				\$13,525	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1121054			\$434,544	\$965,369	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF PITTSBURGH	A1122369		\$28,829	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MINNESOTA	A1122742		\$29,860	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1122838				\$140,398	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF WISCONSIN MADISON	A1125053		\$35,002	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1127365				\$307,395	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1128729			\$195,423	\$495,151	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1129191				\$116,073	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A1131566		\$49,268	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1132348				\$462,260	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF IOWA	A1132402		\$148,311	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ICAHN SCHOOL OF MEDICINE	A1132405		\$115,984	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MINNESOTA	A1134406		\$21,095	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MASSACHUSETTS	A1134770		\$47,291	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1134937				\$532,828	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1136718			\$339,804	\$418,130	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1138965				\$290,592	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ARIZONA STATE UNIVERSITY	A1138993		\$82,844	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1139381				\$164,734	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MICHIGAN	A1141591		\$342,107	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1141765				\$177,760	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1142702				\$85,658	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1143791			\$128,887	\$431,692	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1143882			\$14,167	\$224,447	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOAN & SANFORD I. WEILL MEDICAL COLLEGE	A1144301		\$22,840	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF VIRGINIA	A1145108		\$253,435	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1145356				\$13,167	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1146431				\$108,914	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1146804				\$5,161	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1147652				\$120,835	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ICAHN SCHOOL OF MEDICINE	A1148963		\$18,783	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1150100				\$528,624	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1150649				\$91,099	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1151208			\$8,708	\$91,733	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1152042			\$124,582	\$173,687	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1152318				\$84,287	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BOSTON CHILDREN'S HOSPITAL	A1154470		\$5,311	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF VIRGINIA	A1154598		\$12,795	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	A1154659		\$5,394	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1154927			\$15,911	\$85,044	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1155378				\$71,153	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1155826				\$281,153	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ARIZONA STATE UNIVERSITY	A1155907		\$108,298	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1157328				\$245,686	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1158813				\$60,658	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1159230				\$133,358	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1162678			\$2,911	\$354,926	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MINNESOTA	A1162699		\$10,729	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1163302				\$51,539	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A1164562		\$130,719	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		STINGINN, LLC	A1165061		\$65,087	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		NORTHEASTERN UNIVERSITY	A1167700		\$32,917	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1169530				\$92,218	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1170649				\$230,849	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CONNECTICUT	A121747		\$107,391	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A133144				\$440,593	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A148793				\$300,683	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A152417				\$25,297	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A157266		\$418,899	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A171106			\$10,668	\$608,414	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A189714				\$517,427	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A191594			\$179,945	\$371,120	\$14,515,997	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144233				\$81,191	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65841				\$630,563	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM75148				\$244,779	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063904			\$73,916	\$216,501	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM075148				\$62,750	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM08685				\$451,996	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		CORNELL COLLEGE-VET MEDICINE	GM105688		\$67,416	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF MINNESOTA	GM118079		\$5,532	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF MINNESOTA	GM120079		\$1,008	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM123757			\$84,261	\$174,891	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM125633				\$2,332	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM126086				\$93,675	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128253			\$5,118	\$166,761	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128579				\$173,837	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128594				\$62,376	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM129201				\$41,047	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130556			\$225,603	\$359,014	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132095				\$365,504	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132100				\$256,761	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM134732				\$520,037	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM135488				\$251,661	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136262				\$460,662	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136869				\$242,081	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF PUERTO RICO	GM137368		\$75,542	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM140487	MEDICAL CENTER			\$402,056	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM141003			\$125,051	\$386,703	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		SOUTHCENTRAL FOUNDATION	GM142122		\$72,093	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM143949				\$263,626	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144351			\$32,243	\$146,602	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144393				\$162,633	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM146651				\$67,674	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM147134				\$112,631	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM28157				\$54,923	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM55252				\$436,170	\$7,810,435	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		JOHNS HOPKINS UNIVERSITY	HD100540		\$14,774	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		ARIZONA STATE UNIVERSITY	HD102615		\$167,455	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MASSACHUSETTS GENERAL HOSPITAL	HD103099		\$24,092	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103498			\$46,861	\$101,276	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF KANSAS MEDICAL CENTER	HD105714		\$50,677	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD106096				\$29,197	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		SEQUITUR HEALTH CORPORATION	HD107897		\$95,056	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		BINGHAMTON UNIVERSITY	HD108477		\$3,751	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MINNESOTA	HD44763		\$202,670	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD65987				\$574,456	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD79439				\$166,595	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF TEXAS MEDICAL BRANCH	HD84423		\$96,157	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD84423				\$131,083	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF PITTSBURGH	HD86843		\$56,926	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF VIRGINIA	HD87413		\$29,833	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MOORHOUSE SCHOOL OF MEDICINE	HD97843		\$10,148	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF PENNSYLVANIA	HD98269		\$1,700	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD99147				\$296,542	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	LM13438				\$41,125	\$2,093,513	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68509				\$44,776	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF WISCONSIN MADISON	AG027161		\$51,940	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	AG03949		\$93,563	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	AG057437		\$210,547	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG058812				\$155,667	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		INNOVATIVE DESIGN LABS INC.	AG06077		\$125,958	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		DUKE UNIVERSITY	AG061359		\$10,556	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG061796				\$701,844	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG062110				\$305,212	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BOSTON UNIVERSITY	AG062348	\$15,118	\$127,510	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG067593				\$1,075,999	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG06786			\$19,754	\$3,636,972	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF TEXAS AT AUSTIN	AG078533		\$306	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA SAN DIEGO	AG10483		\$7,589	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG11378				\$1,164,513	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG13925			\$138,228	\$965,086	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG16574				\$56,774	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG23438		\$16,850	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA SAN DIEGO	AG24904		\$594,295	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG27924				\$697,363	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG32438		\$228,991	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG37491				\$673,606	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG41851				\$454,078	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG44170			\$24,325	\$1,342,981	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF MINNESOTA	AG44342		\$4,606	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG44615				\$592,835	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG45779				\$258,332	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF FLORIDA	AG46139		\$8,367	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG46139			\$1,755,163	\$4,373,904	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG46205				\$456,046	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG49672				\$145,505	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA SAN DIEGO	AG49810		\$11,096	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG50603				\$741,254	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	AG51406		\$88,622	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG52425			\$31,554	\$224,988	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF PENNSYLVANIA	AG52943		\$22,369	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG53229				\$188,312	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG53267		\$34,167	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	AG53798		\$43,853	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		MASSACHUSETTS GENERAL HOSPITAL	AG54029		\$410,990	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG54199			\$105,132	\$520,603	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG54449				\$520,219	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG54454				\$561,088	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BRIGHAM AND WOMENS HOSPITAL	AG54672		\$319,408	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	AG54787		\$40,164	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG55151			\$25,010	\$811,937	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		INNOVATIVE DESIGN LABS INC.	AG55152		\$3,258	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BANNER ALZHEIMER'S INSTITUTE	AG55444		\$8,903	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		ARIZONA STATE UNIVERSITY	AG55469		\$17,147	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG55529			\$96,520	\$563,224	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG55549				\$139,453	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		SANFORD-BURNHAM MEDICAL	AG56130		\$166,414	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG56255			\$347,944	\$602,750	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		COLUMBIA UNIVERSITY	AG56270		\$111,876	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BOSTON UNIVERSITY	AG56318		\$183,158	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG56366			\$88,993	\$522,333	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG56639		\$518	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	AG56933		\$185,841	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG57015				\$125,698	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG57052				\$243,774	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG57181			\$32,502	\$1,103,558	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		INDIANA UNIVERSITY	AG57195		\$774,370	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	AG57437		\$368,638	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		NORTHWESTERN UNIVERSITY	AG57441		\$13,705	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG57493				\$455,628	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF NEW SOUTH WALES	AG57531		\$17,505	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG57547			\$1,195,833	\$1,542,924	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BARROW NEUROLOGICAL INSTITUTE	AG57708		\$89,108	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG58266			\$34,217	\$466,569	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG58560				\$39,202	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF MELBOURNE	AG58676		\$23,701	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		HENNEPIN HEALTHCARE RESEARCH	AG58729		\$105,787	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG58738				\$620,326	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG58798				\$245,895	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA SAN FRANCISCO	AG59009		\$8,636	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		DUKE UNIVERSITY	AG59093		\$169,179	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE	AG59417		\$34,357	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF MINNESOTA	AG59654		\$3,679	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG59798		\$51,290	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG60139				\$61,128	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	AG60502		\$68,723	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		DANA-FARBER CANCER INSTITUTE	AG60626		\$116,986	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG60637			\$87,421	\$446,475	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG60920				\$650,034	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		PARTNERS HEALTH CARE RES MGMT	AG61100		\$118,887	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG61456			\$336,439	\$872,597	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	AG61848		\$205,040	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62077				\$597,768	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62104				\$60,576	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62110				\$343,609	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF MINNESOTA	AG62135		\$248,075	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	AG62171		\$91,234	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62413			\$796,293	\$3,118,082	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62436			\$23,993	\$278,255	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62580				\$52,159	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		THE UNIVERSITY OF ARIZONA	AG62620		\$19,919	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62677				\$3,165,142	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA BERKELEY	AG62689		\$343,998	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		ARIZONA STATE UNIVERSITY	AG62823		\$103,912	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG62859				\$786,644	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	AG63689		\$565,070	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG63707				\$310,430	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG63780				\$359,409	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG63911			\$6,847,383	\$11,352,758	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG64029				\$136,658	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG64159				\$86,589	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BRIGHAM AND WOMENS HOSPITAL	AG64165		\$67,311	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		SEATTLE INSTITUTE OF BIOMEDICAL CLINICAL RESEARCH	AG64271		\$6,095	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG64804				\$50,083	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		MINNESOTA HEALTHSOLUTIONS CORPORATION	AG65088		\$69,486	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		MEDICAL CARE CORPORATION	AG65126		\$12,075	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65143				\$136,476	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65154			\$1,280,349	\$1,955,278	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		DUKE UNIVERSITY	AG65188		\$118,144	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		AMERICAN FEDERATION FOR AGING RESEARCH	AG65204		\$41,956	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65219				\$475,821	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BETH ISRAEL DEACONESS MEDICAL	AG65311		\$22,242	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65639				\$113,649	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65653				\$100,653	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65660				\$47,480	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG65868				\$204,533	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		ARIZONA STATE UNIVERSITY	AG65942		\$2,232	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		COLUMBIA UNIVERSITY	AG66134		\$19,950	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG66395				\$492,703	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG66429				\$338,774	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		MASSACHUSETTS INSTITUTE OF TECHNOLOGY	AG67151		\$247,725	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UCB PHARMA, INC.	AG67418		\$342,610	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG67593				\$237,347	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		INDIANA UNIVERSITY	AG67631		\$21,388	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG67763			\$88,627	\$511,578	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG68007				\$371,986	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		NORTH DAKOTA STATE UNIVERSITY	AG68034		\$156,156	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68047				\$99,969	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68048				\$325,345	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	AG68054		\$134,722	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68076				\$371,958	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF FLORIDA	AG68128		\$63,008	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BETH ISRAEL DEACONESS MEDICAL	AG68141		\$65,746	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68182				\$514,902	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68192				\$966,237	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68206				\$696,606	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68368				\$145,321	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		ST. JUDE CHILDREN'S HOSPITAL	AG68581		\$444,612	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG68620				\$202,553	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG69052				\$563,586	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BANNER ALZHEIMER'S INSTITUTE	AG69453		\$257,991	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF TEXAS	AG69690		\$68,922	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG69701			\$2,979,015	\$5,898,525	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UTAH STATE UNIVERSITY	AG69745		\$13,278	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG69767			\$19,124	\$132,231	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG70113				\$142,578	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG70486				\$63,735	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG71190				\$615,898	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG71226				\$313,013	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG71513				\$74,900	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG71686				\$517,185	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG71754		\$1,219,107	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG71934			\$34,801	\$141,053	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		WASHINGTON UNIVERSITY	AG72122		\$50,576	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG72301			\$485	\$260,213	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG72719				\$431,774	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF TEXAS HOUSTON	AG72799		\$249,973	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG72898				\$389,029	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		BANNER ALZHEIMER'S INSTITUTE	AG72980		\$243,944	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF CONNECTICUT	AG73119		\$24,906	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	AG73267		\$16,089	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG73282				\$368,512	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		HARVARD UNIVERSITY	AG73341		\$2,324	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		GEORGIA INSTITUTE OF TECHNOLOGY	AG73434		\$16,544	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG73726				\$105,806	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		HEBREW REHABILITATION CENTER	AG73886		\$9,927	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG73967				\$204,073	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG73987				\$132,906	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		MINNESOTA HEALTHSOLUTIONS CORPORATION	AG74127		\$48,398	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866		UNIVERSITY OF FLORIDA	AG74867		\$19,599	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG74883				\$5,537	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG75227				\$82,265	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG75802			\$610,917	\$2,196,047	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG76122				\$57,692	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG76163				\$262,853	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG76469				\$228,640	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG76515				\$281,331	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG76662				\$33,203	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG77706				\$25,933	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG77771				\$5,177	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG78179				\$76,853	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG78555				\$11,790	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG78615			\$16,356	\$40,702	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
AGING RESEARCH	93.866	AG79113				\$31,099	\$82,820,629	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867		JAEB CENTER FOR HEALTH RESEARCH	EY11751		\$218,290	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867		JAEB CENTER FOR HEALTH RESEARCH	EY14231		\$33,869	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
VISION RESEARCH	93.867	EY21727			\$29,817	\$320,139	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867		OHIO STATE UNIVERSITY	EY22124		\$110,258	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867		NEW YORK SCHOOL OF MEDICINE	EY26869		\$59,278	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867		JAEB CENTER FOR HEALTH RESEARCH	EY30030		\$16,311	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867		ABBE VISION INC.	EY30819		\$11,608	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867	EY31301				\$445,326	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
VISION RESEARCH	93.867	EY31758				\$151,936	\$1,367,015	RESEARCH AND DEVELOPMENT	\$425,554,624
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934			\$240,134	\$544,584	\$732,337	RESEARCH AND DEVELOPMENT	\$425,554,624
MEDICAL LIBRARY ASSISTANCE	93.879		ARIZONA STATE UNIVERSITY	LM13438		\$157,803	\$732,337	RESEARCH AND DEVELOPMENT	\$425,554,624
MEDICAL LIBRARY ASSISTANCE	93.879		UNIVERSITY OF NORTH CAROLINA	LM13606		\$29,950	\$732,337	RESEARCH AND DEVELOPMENT	\$425,554,624
PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	HP33881			\$387,200	\$650,442	\$650,442	RESEARCH AND DEVELOPMENT	\$425,554,624
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889		MINNESOTA DEPARTMENT OF HEALTH	MDH10327		\$216,885	\$397,709	N/A	\$0
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	47383				\$180,824	\$397,709	N/A	\$0
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		STELLENBOSCH UNIVERSITY	TW12265		\$5,726	\$5,726	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	16X237	LEIDOS BIOMEDICAL RESEARCH	16X237		\$526,297	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75A50120C00096				\$1,116,680	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75D30119C06088			\$88,087	\$110,253	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75D30120C07986	HEALTH PARTNERS INSTITUTE	75D30120C07986		\$33,390	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75D30121C10297	CHILDREN'S HOSPITAL OF BOSTON	75D30121C10297		\$8,417	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N91019C00035	NVIGEN, INC.	75N91019C00035		\$17,531	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N91020F00030				\$594	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N91021P00840				\$90,256	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N92019D00031	BOSTON UNIVERSITY	75N92019D00031		\$53,937	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N92021P00132				\$42,829	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N93019C00052	UNIVERSITY OF GEORGIA	75N93019C00052		\$206,516	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75N97019P00280	THE BROAD INSTITUTE, INC.	75N97019P00280		\$23,828	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	75Q80120D00005			\$130,412	\$330,980	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	80JSC022F0146	UNIVERSITY OF COLORADO	80JSC022F0146		\$19,726	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	AWD101462	UNIVERSITY OF CHICAGO	AWD101462		\$54,215	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHNS-2-68-2018-00010I	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	HHNS-2-68-2018-00010I		\$174,762	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-N-261-2012-00042I			\$105,294	\$400,796	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-N-261-2016-00024I				\$72,133	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-N-273-2018-00005I	SOCIAL AND SCIENTIFIC SYSTEMS	HHS-N-273-2018-00005I		\$413	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-N-275-2018-00003I	DUKE UNIVERSITY	HHS-N-275-2018-00003I		\$22,965	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-N-275-2018-00005I			\$453,615	\$1,204,159	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-O-100-2016-00009C				\$44,557	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-P-233-2015-00128I	CARRADORA HEALTH	HHS-P-233-2015-00128I		\$11,157	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	HHS-P-233-2016-00031I	JBS INTERNATIONAL	HHS-P-233-2016-00031I		\$1,707	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	N00024-13-D-6400	JOHNS HOPKINS UNIVERSITY	N00024-13-D-6400		\$103,035	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	N02-CM-62212	THE CHILDRENS HOSPITAL OF PHILADELPHIA	N02-CM-62212		\$8,861	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	PC35143	UNIVERSITY OF IOWA	PC35143		\$158,218	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
CONTRACT	93.RD	W911QY-20-9-0012	JOHNS HOPKINS UNIVERSITY	W911QY-20-9-0012		\$12,871	\$4,851,083	RESEARCH AND DEVELOPMENT	\$425,554,624
MILITARY HEALTH PROFESSIONS SCHOLARSHIPS	93.U01	OFFICE OF THE SURGEON GENERAL				\$232,645	\$232,645	N/A	\$0
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$44,904,693	\$393,272,739			
TOTAL EXPENDITURES OF FEDERAL AWARDS					\$47,352,958	\$446,033,097			

Please Note:

Italicized award lines indicate pass-through funding

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance



**Schedule of Expenditures of Florida State Financial Assistance
Year Ended December 31, 2022**

Sponsor/CSFA Description/Project Description	CSFA Number	Contract / Grant / Subaward Number	Expenditures	Pass-Through to Subrecipients
STATE OF FLORIDA				
Department of Elder Affairs				
Direct Awards				
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZ108	\$ 96,059	\$ -
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZ707	88,323	-
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZ908	74,977	-
Subtotal Direct Awards			<u>259,359</u>	<u>-</u>
Total Department of Elder Affairs			<u>259,359</u>	<u>-</u>
Department of Health				
Direct Awards				
James and Esther King Biomedical Research Program	64.041	20K02	295,172	-
Bankhead-Coley Cancer Research Program	64.078	22B08	62,898	-
Bankhead-Coley Cancer Research Program	64.078	8BC01	(54,858)	-
Bankhead-Coley Cancer Research Program	64.078	MOG13	59,138	-
Endowed Chair for Cancer Research	64.130	MOG07	2,960,065	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	7AZ22	(462)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	8AZ07	(1,842)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	8AZ08	11,581	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	9AZ08	7,906	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	9AZ09	(1,187)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A10	(8,225)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A20	40,636	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A22	3,608	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A04	36,907	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A05	30,138	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A06	36,956	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A07	69,312	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A08	30,308	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A09	140,686	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22K01	108,027	-
Subtotal Direct Awards			<u>3,826,764</u>	<u>-</u>
Total Department of Health			<u>3,826,764</u>	<u>-</u>
Total Expenditures of State Financial Assistance			<u>\$ 4,086,123</u>	<u>\$ -</u>

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance

December 31, 2022

1. Significant Accounting Policies

The accompanying schedules of expenditures of federal awards and Florida state financial assistance (the Schedules) include the federal and Florida state grant activity of Mayo Clinic (the Clinic) under programs of the federal and Florida state government for the year ended December 31, 2022. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Because the Schedules only present a selected portion of the operations of the Clinic, they are not intended to, and do not, present the consolidated financial position, results of operations, or cash flows of the Clinic.

Expenditures reported in the Schedules are reported on the cash basis of accounting, except for Assistance Listing No. 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund and the Student Financial Assistance Cluster, which are reported on the accrual basis of accounting. Under the cash basis, expenditures are recognized when paid rather than when the obligation is incurred. Such expenditures are reported following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts reported on the Schedules represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

2. 10% De Minimis Cost Rate

Indirect cost rates for Mayo were based on applicable U.S. Department of Health and Human Services (HHS) negotiated rates, the 10% de minimis indirect cost rate allowed by the Uniform Guidance, or sponsor-specific (capped) rates.

3. Section 202 Direct Loans and Federal Direct Loans

The Supportive Housing for the Elderly, Section 202 Direct Loan (Assistance Listing No. 14.157), is considered a federal award until the outstanding balance is paid in full. At December 31, 2022, Luther Lakeside Apartments, Inc.'s outstanding balance is \$113,743 and Bloomer Lakeview, Inc.'s outstanding balance is \$189,255.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (continued)

3. Section 202 Direct Loans and Federal Direct Loans (continued)

During the year, the Clinic expended \$16,337,425 in Federal Direct Student Loans (Assistance Listing No. 84.268), which includes Direct Stafford Loan and Parent Loan for Undergraduate Students from the federal government. The federal government is responsible for billings and collections of the loans. The Clinic assists the federal government by processing the applications and applying funds to student accounts from the federal government. Since this program is administered by the federal government, new loans made in the fiscal year ended December 31, 2022, related to Federal Direct Student Loans, are considered current year federal expenditures, whereas the outstanding loan balances are not.

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Board of Trustees, Chief Executive Officer and
President, and Chief Financial Officer
Mayo Clinic

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2022, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated February 17, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Clinic’s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Clinic’s internal control. Accordingly, we do not express an opinion on the effectiveness of the Clinic’s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Clinic's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

February 17, 2023

Report of Independent Auditors on Compliance for Each Major Federal Program
and State Financial Assistance Project and Report on Internal Control Over
Compliance Required by the Uniform Guidance and Chapter 10.650,
Rules of the Auditor General of the State of Florida

Board of Trustees, Chief Executive Officer and
President, and Chief Financial Officer
Mayo Clinic

**Report of Independent Auditors on Compliance for Each Major Federal Program and
State Financial Assistance Project**

Opinion on Each Major Federal Program and State Financial Assistance Project

We have audited the Mayo Clinic's (the "Clinic") compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* and the Florida Department of Financial Services' *State Projects Compliance Supplement* that could have a direct and material effect on each of the Clinic's major federal programs and state financial assistance project, respectively, for the year ended December 31, 2022. The Clinic's major federal programs and state financial assistance project are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs and major state financial assistance project for the year ended December 31, 2022.

Basis for Opinion on Each Major Federal Program and State Financial Assistance Project

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance); and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Our responsibilities under those standards, the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida* are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Clinic and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program and state financial assistance project. Our audit does not provide a legal determination of the Clinic's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Clinic's federal programs and state projects.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Clinic's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Clinic's compliance with the requirements of each major federal program and state financial assistance project as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Clinic's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.

- Obtain an understanding of the Clinic’s internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, but not for the purpose of expressing an opinion on the effectiveness of the Clinic’s internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida* and which are described in the accompanying schedule of findings and questioned costs, as follows:

Finding No.	Assistance Listing or CSFA No.	Program (or Cluster) Name	Compliance Requirement
2022-002	93.310, 93.394, 93.397, and 93.838	Research and Development Cluster	I. Procurement, Suspension and Debarment
2022-003	84.063 and 84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N13. Gramm-Leach-Bliley Act – Student Information Security
2022-006	64.130	Endowed Chair for Cancer Research	H. Reporting

Our opinion on each major federal program and state financial assistance project is not modified with respect to these matters.

We performed audit procedures with respect to the Student Financial Assistance Cluster major federal program related to compliance requirements in Special Test and Provision N13, *Gramm-Leach Bliley Act – Student Information Security* as outlined in the OMB *Compliance Supplement* for the year ended December 31, 2022. We determined whether the Clinic has designated an individual to coordinate the information security program. We determined whether the Clinic performed a risk assessment that addresses the three required areas noted in 16 CFR 314.4 (b) and whether the Clinic documented a safeguard for each risk identified from the three required to be risk-assessed by 16 CFR 314.4 (b). Our audit procedures did not evaluate whether the designated individual that coordinated the information security program is competent to oversee the program nor whether the individual possessed the adequate authority to carry out those duties. Our audit procedures also did

not determine whether the risk assessment sufficiently addressed the required areas, whether the risks identified are the appropriate risks or that the identified risks appear to be a complete list. Further, our audit procedures did not determine whether the documented safeguards have been put in place or that they will effectively mitigate, reduce, or even address the identified risks. Our opinion on the Student Financial Assistance Cluster major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on the Clinic's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be material weaknesses and significant deficiencies.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program or state financial assistance project on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program or state financial assistance project will not be prevented, or detected and corrected, on a timely basis. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses as follows:

Finding No.	Assistance Listing or CSFA No.	Program (or Cluster) Name	Compliance Requirement
2022-001	84.063 and 84.268	Student Financial Assistance Cluster	A. Activities Allowed or Unallowed; E. Eligibility; L. Reporting; and N. Special Tests and Provisions: N2. Disbursements to or on Behalf of Students and N4. Enrollment Reporting

Finding No.	Assistance Listing or CSFA No.	Program (or Cluster) Name	Compliance Requirement
2022-003	84.063 and 84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N13. Gramm-Leach-Bliley Act ☐ Student Information Security
2022-006	64.130	Endowed Chair for Cancer Research	H. Reporting
2022-007	Various	Research and Development Cluster	A. Activities Allowed or Unallowed and B. Allowable Costs/Cost Principles

A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program or state financial assistance project that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be significant deficiencies as follows:

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2022-002	93.310, 93.394, 93.397, and 93.838	Research and Development Cluster	I. Procurement, Suspension and Debarment
2022-004	84.063 and 84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N4. Enrollment Reporting
2022-005	84.063 and 84.268	Student Financial Assistance Cluster	A. Activities Allowed or Unallowed and E. Eligibility

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on the Clinic's response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

August 7, 2023

Mayo Clinic

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2022

Section I – Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified

Internal control over financial reporting:

Material weakness(es) identified? Yes X No
Significant deficiency(ies) identified? Yes X None Reported

Noncompliance material to financial statements noted?

Yes X No

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified? X Yes No
Significant deficiency(ies) identified? X Yes None Reported

Type of auditor’s report issued on compliance for major federal programs:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

X Yes No

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor’s Results (continued)

Identification of major federal programs:

Assistance Listing Numbers	Name of Federal Program or Cluster
Multiple 84.063 and 84.268	Research and Development Cluster Student Financial Assistance Cluster

Dollar threshold used to distinguish between
Type A and Type B programs: \$ 3,000,000

Auditee qualified as low-risk auditee? **Yes** X **No**

Florida State Financial Assistance Projects

Internal control over major state financial
assistance projects:

Material weakness(es) identified? X **Yes** **No**
Significant deficiency(ies) identified? **Yes** X **None Reported**

Type of auditor’s report issued on compliance
for major state financial assistance projects: Unmodified

Any audit findings disclosed that are required
to be reported in accordance with Chapter
10.650, *Rules of the Auditor General of the
State of Florida*? X **Yes** **No**

Identification of major state project:

State CSFA Numbers	Name of State Project
64.130	Endowed Chair for Cancer Research

Dollar threshold used to distinguish between
Type A and Type B programs: \$750,000

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

None identified.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs

Finding 2022-001 – Information Technology General Controls

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster/Program: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

Mayo Clinic (the Clinic) did not implement all Complementary User Entity Controls (CUECs) as prescribed in the Ellucian SOC 1 Report that are required to be in place to support effective information technology general controls (ITGCs) for the Banner application. The controls that were not specifically implemented relate to user access review. Additionally, user provisioning and user termination processes were not operating as designed. As a result, Banner ITGCs cannot be relied upon in the period of audit.

There is a risk the data relevant to the SFA Cluster program stored within the student financial aid system may be inappropriately created or modified. A user access review was not performed during the current period. For the remainder of the CUECs, evidence of the operation of controls identified to address this risk during the fiscal period under audit was not appropriately retained.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Cause:

Management did not appropriately implement a user access review. Management did not retain sufficient supporting documentation to evidence that the new user provisioning and termination controls, as required by the CUECs prescribed in the Ellucian SOC 1 Report, were designed effectively and placed in operation during the period under audit.

Effect or potential effect:

Effective testing of the required CUECs is to support effective ITGCs over the Banner application. As a result, the Banner application cannot be relied on for the audit period.

Questioned costs:

None.

Context:

We reviewed evidence over the testing of the required CUECs and noted the evidence was incomplete and insufficient to conclude on the effective ITGCs over the Banner application. These controls specifically relate to user access review, user provisioning, and user termination. As a result, Banner ITGCs cannot be relied upon in the period of audit.

Total expenditures for the Student Financial Assistance Cluster were \$16,350,962 for the year ended December 31, 2022.

Identification as a repeat finding, if applicable:

This is a not a repeat finding from the prior year.

Recommendation:

Management should complete the implementation for all required CUECs prescribed within the Ellucian SOC 1 Report and retain documentation of the operation of controls.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Views of responsible officials:

Mayo Clinic IT will work with the Student Financial Aid office to review the risk rating given to the Banner application. A complete user access review based on job roles will be completed for 2023. The review will include each employee's assigned functions within the Banner system. The user provisioning process will also be updated to include the functions the user will be receiving. Enhanced documentation will be retained for user terminations and other system reports required to complete testing of the Banner controls.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2022-002 – Procurement, Suspension and Debarment

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services

Federal Cluster: Research and Development (R&D)

Pass-Through Entities: University of Iowa (93.397) and NYU Grossman School of Medicine (93.838)

Assistance Listing Nos.: 93.310, 93.394, 93.397 and 93.838

Award Numbers: OD23121, CA212162, CA97274 and HL16847

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Section 200.320(b) of the Uniform Guidance states the following regarding formal procurement methods to be followed:

“When the value of the procurement for property or services under a Federal financial assistance award exceeds the simplified acquisition threshold (SAT), or a lower threshold established by a non-Federal entity, formal procurement methods are required. Formal procurement methods require following documented procedures. Formal procurement methods also require public advertising unless a non-competitive procurement can be used in accordance with § 200.319 or paragraph (c) of this section.”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Section 200.320(c) of the Uniform Guidance states the following regarding noncompetitive procurement:

“There are specific circumstances in which noncompetitive procurement can be used. Noncompetitive procurement can only be awarded if one or more of the following circumstances apply:

- (1) The acquisition of property or services, the aggregate dollar amount of which does not exceed the micro-purchase threshold (see paragraph (a)(1) of this section);
- (2) The item is available only from a single source;
- (3) The public exigency or emergency for the requirement will not permit a delay resulting from publicizing a competitive solicitation;
- (4) The Federal awarding agency or pass-through entity expressly authorizes a noncompetitive procurement in response to a written request from the non-Federal entity; or
- (5) After solicitation of a number of sources, competition is determined inadequate.”

Condition:

Four federal procurements conducted in fiscal year 2022 in excess of the SAT of \$250,000 were not competitively bid as required under Uniform Guidance Section 230.320(b) nor was a competitive bid exception documented to support the lack of formal proposals in accordance with Clinic procurement policies and procedures and Uniform Guidance Section 230.320(c). In addition, for one procurement, the Clinic did not timely document its independent suspension and debarment check at the time of procurement as required by its procurement justification form.

Cause:

While management has internal controls in place to review procurements > \$25,000 to ensure they are documented in accordance with the Clinic’s procurement, suspension and debarment policies and procedures, they are not robust enough to identify procurement transactions that are not in accordance with the Clinic’s policies and procedures.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Effect or potential effect:

The Clinic's internal controls over procurement were not properly followed during the fiscal year. In addition, the Clinic did not follow the Uniform Guidance requirements related to purchases in excess of the SAT.

Questioned costs:

\$1,158,184:

Assistance Listing No. 93.310, OD23121 – \$270,000

Assistance Listing No. 93.394, CA212162 – \$254,125

Assistance Listing No. 93.397, CA97274 – \$254,125

Assistance Listing No. 93.838, HL16847 – \$379,934

Context:

We sampled 16 federal procurements over \$25,000, totaling \$2,839,288, from a population of 91 federal procurements over \$25,000, totaling \$7,490,915. For four of the 16 federal procurements tested totaling \$1,158,184, the amount of the procurement exceeded the SAT of \$250,000. Based on the Uniform Guidance and Clinic procurement policies, competitive proposals would be required; however, no competitive bidding was performed. For one of the 16 procurements tested totaling \$257,100, the independent suspension and debarment check to be performed at the time of procurement was not performed until approximately seven months later.

Procurement-related expenditures are approximately 7% of total Federal expenditures for the R&D Cluster of \$425,554,624 for the year ended December 31, 2022.

Identification as a repeat finding, if applicable:

The finding is not a repeat finding from the prior year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Recommendation:

The Clinic should ensure that all R&D awards that require procurement of goods and services follow established policies, procedures and internal controls in order to comply with the Uniform Guidance procurement standards. The Clinic should ensure that independent checks for suspension and debarment should be timely completed at the time of procurement in accordance with Clinic documented policies, procedures and internal controls.

Views of responsible officials:

While Mayo Clinic Supply Chain Procurement processes include internal controls and procedures to review submission of Federal Funds documentation, enhanced controls will be evaluated to ensure compliance with competitive bid requirements. A review of risks will be completed with compensating controls added, as necessary.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2022-003 – Gramm-Leach-Bliley Act – Student Information Security (GLBA)

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

16 CFR 314.4(b) requires institutions to “Identify reasonably foreseeable internal and external risks to the security, confidentiality, and integrity of customer information that could result in the unauthorized disclosure, misuse, alteration, destruction or other compromise of such information, and assess the sufficiency of any safeguards in place to control these risks. At a minimum, such a risk assessment should include consideration of risks in each relevant area of your operations, including: (1) Employee training and management; (2) Information systems, including network and software design, as well as information processing, storage, transmission and disposal; and (3) Detecting, preventing and responding to attacks, intrusions, or other systems failures.”

16 CFR 314.4(c) requires institutions to “Design and implement information safeguards to control the risks you identify through risk assessment, and regularly test or otherwise monitor the effectiveness of the safeguards’ key controls, systems, and procedures.”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Condition:

The Clinic has a security risk program in place that follows the National Institute of Standards and Technology (NIST) framework to assess its information technology risks. The program includes: (1) employee training and management; (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

However, for the student financial aid system used by the Clinic, the 2022 NIST risk assessment did not cover (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

Cause:

The Clinic's security risk program did not include the student financial aid information applications.

Effect or potential effect:

The absence of internal controls and policies and procedures could result in the unauthorized disclosure, misuse, alteration, destruction, or other compromise of student account information.

Questioned costs:

None.

Context:

Under an institution's Program Participation Agreement with the U.S. Department of Education and the GLBA, schools must protect student financial aid information, with particular attention to information provided to institutions by the U.S. Department of Education or otherwise obtained in support of the administration of the federal student financial aid programs. Total expenditures for the Student Financial Assistance Cluster were \$16,350,962 for the year ended December 31, 2022.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Identification as a repeat finding, if applicable:

This finding is a repeat of Finding 2021-006 from the prior year.

Recommendation:

We recommend that the Clinic include the student information systems as part of its annual enterprise-wide risk assessment.

Views of responsible officials:

Mayo Clinic Office of Information Security created a corrective action plan in the Fall of 2022. The corrective action plan has been fully implemented as of May 2023. The Department of Education reviewed the corrective action plan and concluded it acceptable to address the auditor finding from audit year 2021.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2022-004 – Enrollment Reporting

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Period: July 1, 2021 through June 30, 2022

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

As part of the review of the monthly SFRNSLC enrollment report prior to its upload to the National Student Clearinghouse (NSC)/National Student Loan Data System, the Financial Aid Director sampled 10 students from the monthly SFRNSLC enrollment report for accuracy against the student records system and sampled 10 students from the student records system for completeness against the monthly SFRNSLC enrollment report. However, evidence was not retained of the students sampled and the specific data validated as part of the review for the period January 1 – June 30, 2022. Management implemented internal controls on July 1, 2022 to include the retention of documentation over its internal controls. This control was tested for the period July 1, 2022 through December 31, 2022 and determined to be operating effectively.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Cause:

Internal controls were not properly designed for the first six months of FY22 to require detailed evidence of the accounts reviewed and related test attributes to be retained.

Effect or potential effect:

An incorrect enrollment report may be submitted.

Questioned costs:

None.

Context:

Total expenditures for the Student Financial Assistance Cluster were \$16,350,962 for the year ended December 31, 2022.

Identification as a repeat finding, if applicable:

This finding is a repeat of Finding 2021-007 from the prior year.

Recommendation:

Management should continue to follow its internal control implemented on July 1, 2022 which documents the review process performed by the Financial Aid Director, including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and sign-off by the Financial Aid Director to evidence performance of the monthly review.

Views of responsible officials:

Mayo Clinic has provided evidence to support internal controls were properly designed to support correct information is being submitted to the National Student Loan Clearinghouse. This process will be continued.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2022-005 – Activities Allowed or Unallowed and Eligibility (Cost of Attendance)

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

Annual cost of attendance (COA) budgets (by program/by enrollment status) uploaded to Mayo Clinic College of Medicine and Science’s student information system by the Program Manager of Student Financial Aid were not reviewed and approved by another individual for accuracy once the upload was complete for the period January 1 – August 31, 2022. Management implemented internal controls on September 1, 2022 to include evidence over review and approval of COA budgets and performed the control for any remaining programs for which COA budgets required upload to the student information system by December 31, 2022. This control was tested for the period September 1, 2022 through December 31, 2022 for two of four programs subject to the new control and determined to be operating effectively.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Cause:

Internal controls were not in place for the first eight months of FY22 to require a secondary review of the data input by the Program Manager of Student Financial Aid.

Effect or potential effect:

COA could be incorrectly uploaded to the student information system, which could cause a student's financial need, and resulting financial aid, to be incorrectly calculated.

Questioned Costs:

None.

Context:

Total expenditures for the Student Financial Assistance Cluster were \$16,350,962 for the year ended December 31, 2022.

Identification as a repeat finding, if applicable:

This finding is a repeat of Finding 2021-008 from the prior year.

Recommendation:

Management should continue to follow its internal control implemented on September 1, 2022 which requires signoff on the annual COA budgets uploaded into the student information system by the Program Manager of Student Financial Aid by a secondary reviewer to ensure accuracy.

Views of responsible officials:

Starting in September 2022, annual cost of attendance budgets uploaded to Mayo Clinic College of Medicine and Science's student information system by the Program Manager of Student Financial Aid are reviewed and approved by another individual for accuracy once the upload was complete. This process will be continued.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2022-006 – Reporting

Information of the state program:

State Grantor: State of Florida Department of Health (DOH)
Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research
Award Number: MOG07
Award Period: 07/01/2014 – 06/30/2023

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 215.97, Florida Single Audit Act, part (2)(j) states, “Internal control over state projects means a process, effected by a nonstate entity’s management and other personnel, designed to provide reasonable assurance regarding the achievement of objectives in the following categories:

1. Effectiveness and efficiency of operations.
2. Reliability of financial operations.
3. Compliance with applicable laws and regulations.”

In addition, Award Number MOG07 states, “Provide the Governor, the President of the Senate, and Speaker of the House of Representatives an annual progress report by December 15 that must include the research chair’s name; the amount of the endowment fund used for the chair’s salary; research responsibilities; the percentage of time devoted to research if the chair also serves as a member of the faculty; research progress; progress toward achieving the goals of the research program; endowment expenditures; balance, interest rate, interest earned on the endowment; and the amount of federal or private grants or donation generated, if any, as a result of the research chair’s efforts.”

Condition:

The annual progress report required by the State of Florida DOH was not submitted timely and no approved extension was obtained. Additionally, there was an error in the amounts reported for Endowment Expenditures and Endowment Balance for one of seven activities under Award Number MOG07.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Cause:

Internal controls were not in place to monitor the due dates for submission of the annual progress report. In addition, internal controls over the review of the annual progress report were not sufficiently precise to detect errors in the reporting of financial data.

Effect or potential effect:

The Clinic is not in compliance with the reporting requirements of the state of Florida project.

Questioned costs:

None.

Context:

The annual progress report was due on December 15, 2022 and was not submitted until May 4, 2023. No approved extension was obtained from the State of Florida DOH.

The annual progress report included seven grant activities under Award Number MOG07. For one of the seven grant activities, errors were noted in two of 11 key data elements, specifically the reported Endowment Expenditures and Endowment Balance (cumulative through November 30, 2022), as follows:

	As Reported	As Corrected	(Under)/Overstated
Endowment Expenditures	\$ 888,494	\$2,000,000	\$(1,111,506)
Endowment Balance	1,111,506	—	1,111,506

Identification as a repeat finding, if applicable:

The finding is not a repeat finding from the prior year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Recommendation:

The Clinic should implement an internal control over the monitoring of due dates of all reports required to be submitted under the State of Florida DOH project to ensure they are reviewed and submitted timely. When required, formal extensions of reporting deadlines should be obtained from the State of Florida DOH. In addition, review controls should be designed with sufficient precision to ensure accuracy of amounts reported in the annual progress report.

Views of responsible officials:

Management agrees that the annual progress report was submitted late. In addition, the report included a reporting error for one of the seven grants within the award. Award number MOG07 has now been fully obligated, and Mayo Clinic is working with the Florida Department of Health to close out the grant.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2022-007 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles (Internal Service Charges)

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services

Pass-Through Entities: University of Iowa (Assistance Listing No. 93.397), Massachusetts General Hospital (Assistance Listing No. 93.853), and UCB Pharma, Inc. (Assistance Listing 93.866)

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 93.350, 93.393, 93.394, 93.395, 93.397, 93.837, 93.847, 93.853, and 93.866

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

Approval of allowability of internal service charges by the Principal Investigator (PI) or appropriate individual with authority on the grant was not consistently maintained at a transactional level during the fiscal year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Cause:

While internal service charges are reviewed for allowability with federal regulations and the terms and conditions of the grant award on a monthly/quarterly basis by the PI as part of the grant's financial statement review, evidence of the monthly/quarterly review by the PI and conclusions reached over allowability is not retained by the Clinic.

Effect or potential effect:

Internal service costs could be charged that are not allowable.

Questioned costs:

None.

Context:

For 35 of 40 internal service charges sampled totaling \$14,322 and \$22,180, respectively, there was insufficient evidence of review and approval of the costs to be charged to the research activity by the PI or authorized grant personnel at the time the cost was incurred.

Internal service charges are \$39,951,909, representing 9.4% of total Federal expenditures for the R&D Cluster of \$425,554,624 for the year ended December 31, 2022.

Identification as a repeat finding, if applicable:

The finding is a partial repeat of Finding 2021-001 in the prior year.

Recommendation:

The Clinic should retain sufficient evidence of the monthly/quarterly review of internal service charges by PIs and the related conclusions reached over allowability.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Views of responsible officials:

Approval of allowability of internal service charges by the PI or appropriate individual with authority on the grant at a transactional level is administratively burdensome. Requests for internal services are initiated by the PI or authorized grant personnel through a variety of internal service provider systems or intake methods which makes standardization across providers and service lines difficult. Further, the PI or authorized grant personnel review grant financial statements regularly to ensure charges to grants are appropriate and request corrections as needed.

Management has implemented, and continues to reinforce, the corrective action plans developed following the completion of prior single audits. Management will consider alternative methods, which may include partnering with internal service providers, to ensure appropriate documentation for review and approval of charges is retained.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2023 Ernst & Young LLP.
All Rights Reserved.

ey.com

Summary Schedule of Prior Audit Findings – For the Years Ended December 31, 2021 and 2020

Finding 2021–001 (and 2020-001)

Federal Program Information

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 47.070, 93.286, 93.310, 93.353, 93.393, 93.394, 93.395, 93.397, 93.399, 93.837, 93.838, 93.846, 93.847, 93.853, 93.865, 93.866, 93.RD

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

Approval of Information System (IS) Programmers internal service charges by the Principal Investigator (PI) or appropriate individual with authority on the grant was not consistently maintained during the fiscal year. In addition, approval for the annual IS Programmer billing rate was not retained.

Recommendation:

The Clinic should ensure that all R&D awards, subawards, and contracts that use IS Programmer services comply with the updated policies, procedures, and internal controls established in October 2020.

Status

Completed. Information Technology (IT) implemented corrective actions as planned. Those corrective actions require that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. IT continues to supplement these corrective actions with additional communications about expectations, and retrospective confirmations of ongoing work to ensure appropriate documentation exists for both new and ongoing work. In addition, management met with staff to identify, or create, the documentation to be retained to support implementation of the IS Programmer rate.

Finding 2021–002 (and 2020-002)

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: January 1, 2021 through December 31, 2021

Summary of Prior Audit Finding

Condition:

The Clinic did not document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

For certain emergency department and physician office visits that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, the Clinic erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

Internal controls over the determination of a patient's uninsured/self-pay status were not operating effectively. In addition, inadequate support was retained in the patient billing and recordkeeping system related to the determination of the patient's uninsured/self-pay status and in some instances, no support was retained.

Refunds required to be made to the HRSA COVID-19 Uninsured Program were not identified.

Furthermore, a risk exists that the data relevant to the HRSA COVID-19 Uninsured Program stored within the patient accounting system may be inappropriately created or modified. Evidence of the operation of controls identified to address this risk during the fiscal period under audit was not retained.

Recommendation:

The Clinic should implement internal controls to document its review and compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement.

Standard policies, procedures, and internal controls over the review for patient insurance coverage and review of credit balances should be updated to address the unique aspects of the HRSA COVID-19 Uninsured Program.

Management should retain documentation of the operation of controls responsive to risks related to the data stored in their IT systems as evidence of control activities.

Status

Completed. A comprehensive review of the coverage rules in Mayo Clinic's Electronic Health Record (EHR) related to the HRSA COVID-19 Uninsured Program was completed December 10, 2021. EHR billing edits were put in place to review claims prior to submission and ensure compliance with the HRSA COVID-19 Uninsured Program. A review of all HRSA COVID-19 Uninsured Program payments made from 2020 through April 30, 2022 were evaluated to ensure compliance with the HRSA COVID-19 Uninsured Program T&Cs. Refunds were identified in the review process and have been expeditiously refunded according the HRSA COVID-19 Uninsured Program requirements.

Finding 2021–003 (and 2020-003)

Federal Program Information

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

The Clinic maintains a monthly balanced scorecard to monitor that that subrecipient risk assessment are being completed timely. For 8 of 12 months during the fiscal year, there was no evidence of review and approval of the calculated metric.

The Clinic’s principal investigators perform monthly/quarterly reviews of subrecipient financial and performance reports; however, documentation was not consistently completed or retained to evidence the results of the monitoring during the fiscal year.

Recommendation:

The Clinic should ensure that evidence is retained to support the operating effectiveness of established internal controls.

Status

Complete. Management has remediated review and approval of the balanced scorecard beginning in 2022.

Management implemented corrective actions immediately following completion of the 2020 single audit in March of 2022. Those corrective actions ensure that proper documentation has been and will continue to be retained to support the operating effectiveness of established internal controls.

Finding 2021–004 (and 2020-004)

Federal Program Information

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

The Clinic does not have an internal control in place over the review and approval of subrecipient invoices to ensure that the payment to the subrecipient is consistent with the terms and conditions of the subaward agreement.

Recommendation:

The Clinic should review its policies and procedures and internal controls over subrecipient cash management to ensure that subrecipients are paid on a cash reimbursement basis.

Status

Management developed corrective actions following completion of the 2020 single audit in March of 2022. Those corrective actions include new controls and enhancements to existing controls and have been implemented.

Finding 2021–005

Federal Program Information

Federal Agencies: United States Department of Education

Federal Cluster: Student Financial Assistance Cluster – Federal Direct Student Loans

Assistance Listing Nos.: 84.268

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Summary of Prior Audit Finding

Condition:

The Mayo Clinic College of Medicine and Science (MCCMS) did not document the components of its quality assurance system for the Federal Direct Loan program for the year ended December 31, 2021, in a single location. In addition, MCCMS did not retain documentation of its periodic monitoring and evaluation of its direct loan quality assurance system, including results of the assessments and whether any updates or changes were required.

Recommendation:

MCCMS should retain documentation of its periodic monitoring and evaluation of the direct loan quality assurance system.

Status

Completed September 30, 2022. MCCM has met the requirements and has taken the following steps during our annual review of policy and procedures:

1. Maintained a single Annual Direct Loan Quality Assurance program document outlining:
 - a. Policies and procedures reviewed
 - b. Outcome of review including changes made
 - c. Name of individual conducting the review
 - d. Date the review occurred
2. Archived a copy of the policy and procedures in our financial aid electronic folder each academic year.
3. Maintained documentation of new federal guidelines or system updates along with confirmation that necessary changes were made according to federal or system requirements.

Finding 2021–006

Federal Program Information

Federal Agencies: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Summary of Prior Audit Finding

Condition:

The Mayo Clinic has a security risk program in place that follows the National Institute of Standards and Technology (NIST) framework to assess its information technology risks. The program includes (1) employee training and management; (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

However, for the student financial aid system used by Mayo Clinic, the 2021 NIST risk assessment did not cover (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

Recommendation:

We recommend that the Mayo Clinic include the student information systems as part of its annual enterprise-wide risk assessment.

Status

Mayo Clinic Office of Information Security created a corrective action plan in the Fall of 2022. The corrective action plan has been fully implemented as of May 2023. The Department of Education reviewed the corrective action plan and concluded it acceptable to address the auditor finding from audit year 2021. The following steps have been completed to address the gap identified:

1. Compare the scope of the Mayo Clinic Information Security annual risk assessment and the requirements of the Department of Education, under the Gramm-Leach-Bliley Act and identify any gaps.
2. Determine if edits to the existing annual risk assessment will close the gaps or if a separate risk assessment would be appropriate.
3. Once best approach is determined, complete the risk assessment.

Finding 2021–007

Federal Program Information

Federal Agencies: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Summary of Prior Audit Finding

Condition:

As part of the review of the monthly SFRNSLC enrollment report prior to its upload to the National Student Clearinghouse (NSC)/National Student Loan Data System, the Financial Aid Director sampled 10 students from the monthly SFRNSLC enrollment report for accuracy against the student records system and sampled 10 students from the student records system for completeness against the monthly

SFRNSLC enrollment report. However, evidence was not retained of the students sampled and the specific data validated as part of the review.

Recommendation:

Specific elements of the review process should be documented by the Financial Aid Director including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and signed off by the Financial Aid Director to evidence performance of the monthly review.

Status

Completed. As stated, a student sample is reviewed for accuracy prior to submitting the report to the clearinghouse each month. Beginning July 1, 2022, to provide evidence, the Financial Aid Director retains the names of the student along with the items validated. This is communicated in an email from the Director to our Assistant Registrar each month prior to submitting the enrollment report to the clearinghouse. Assistant Registrar retains a copy of the email in our registrar electronic folder within the applicable month archive.

Finding 2021–008

Federal Program Information

Federal Agencies: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Summary of Prior Audit Finding

Condition:

Annual cost of attendance (COA) budgets (by program/by enrollment status) uploaded to Mayo Clinic College of Medicine and Science's student information system by the Program Manager of Student Financial Aid are not reviewed and approved by another individual for accuracy once the upload was complete.

Recommendation:

The annual COA budgets uploaded into the student information system should be reviewed and approved by a secondary individual for accuracy once the upload by the Program Manager of Student Financial Aid is complete. This review should be documented and signed off by the secondary reviewer.

Status

Completed. The COA budget items are reviewed several times during the specific educational program setup in our Banner student record system. Each review is documented in a dashboard retained in our financial aid electronic folder. Previously each review was completed by one person. Beginning September, 1, 2022, in order to maintain a second level of review, we have delegated a second financial aid team member to complete a review. We maintain evidence of the name of each individual completing the COA review and the date the review occurred.

Finding 2021–009

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.498, COVID-19 Provider Relief Fund and American Rescue Plan (ARP)
Rural Distribution
Award Numbers: Various
Award Period: January 1, 2021 through December 31, 2021

Summary of Prior Audit Finding

Condition:

Management did not retain supporting documentation over its approval of expenses reported to HRSA in the HHS portal. While management had a robust process to identify and review expenses for allowability under the PRF program, sufficient supporting documentation was not retained to support the process.

Recommendation:

Management should reassess its internal controls over the review and approval of allowability of expenditures.

Status

Completed. This award has ended, and no further expenditures are expected. The review and approval of allowability of expenditures that extends to these funds will no longer be required. Should there be any new or additional funding related to ARP, management will reassess its documentation maintenance practices.



Corrective Action Plan

Finding 2022-001

Federal Program Information

Federal Agency: United States Department of Education

Assistance Listing Nos.: 84.063 and 84.268, Student Financial Assistance Cluster

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Corrective Action Planned

Mayo Clinic Information Technology will work with the Student Financial Aid office to review the risk rating of the Banner application. A complete user access review based on job roles will be completed for 2023. To improve the speed and accuracy of the completion of these requests, we will be working with the Identity Management Platform team to add the Banner application into SailPoint for access management and review.

Persons Responsible for Corrective Action

Alec Haws, ETC Education Application Analyst

Raj Sanwal, Lead IT Analyst/Programmer

Target Completion Date

October 31, 2023

Finding 2022-002

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services

Federal Cluster: Research and Development (R&D)

Pass-Through Entities: University of Iowa (93.397) and NYU Grossman School of Medicine (93.838)

Assistance Listing Nos.: 93.310, 93.394, 93.397 and 93.838

Award Numbers: OD23121, CA212162, CA97274 and HL16847

Award Periods: Various

Corrective Action Planned

Researchers and/or their delegates will collaborate timely with appropriate Supply Chain Management team to execute their known procurements and to ensure federal funds documentation is completed. When required for known procurements in excess of \$250,000, researchers and/or their delegates will collaborate timely with Mayo Clinic Supply Chain Contracting team to complete request for proposal (RFP). As of June 2023, an additional compensating control was added to verify RFP documentation meets documentation retention requirements.

Persons Responsible for Corrective Action

Bruce Mairose, SCM Division Chair, Sourcing/Network Management

Target Completion Date

June 30, 2023

Finding 2022-003

Federal Program Information

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Corrective Action Planned

Management agrees that Banner, the primary information system used to capture Federal Direct Loan information, was not specifically identified in the Mayo Clinic Information Security annual risk assessment which was primarily designed for compliance with The Health Insurance Portability and Accountability Act (HIPAA) Security rule.

The following steps have been completed to address the gap identified:

1. Compared the scope of the Mayo Clinic Information Security annual risk assessment and the requirements of the Department of Education, under the Gramm-Leach-Bliley Act and identified any gaps.
2. Edited the existing annual risk assessment to close the gaps.
3. Completed the risk assessment.

Persons Responsible for Corrective Action

Sarah Tyson, Senior Manager—Office of Information Security

Target Completion Date

May 31, 2023

Finding 2022-004

Federal Program Information

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Period: July 1, 2021 through June 30, 2022

Corrective Action Planned

Management retains evidence to support internal controls implemented as of July 1, 2022, to document the review process performed for data submitted to the National Student Loan Clearinghouse, including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and sign-off by the Financial Aid Director to evidence performance of the monthly review.

Persons Responsible for Corrective Action

Anne Dahlen, Director of Student Financial Aid/Registrar

Delores Henke, Assistant Registrar

Target Completion Date

July 1, 2022

Finding 2022-005

Federal Program Information

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Corrective Action Planned

Annual cost of attendance budgets uploaded to Mayo Clinic College of Medicine and Science's student information system by the Program Manager of Student Financial Aid are reviewed and approved by another individual for accuracy once the upload is complete.

Persons Responsible for Corrective Action

Anne Dahlen, Director of Student Financial Aid/Registrar

Maribeth Foerster, Program Manager Student Financial Aid

Target Completion Date

September 30, 2022

Finding 2022-006

Federal Program Information

State Grantor: State of Florida Department of Health (DOH)

Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research

Award Number: MOG07

Award Period: 07/01/2014 – 06/30/2023

Corrective Action Planned

The statute requiring an annual progress report of award MOG07 has been repealed effective 7/1/23 in Chapter 2023-246 of House Bill No. 5303. Mayo Clinic Government Engagement, Research Administration and Research Finance will partner to create a control for any future reporting required to the Florida Department of Health.

Persons Responsible for Corrective Action

Layne Smith, Communication-Policy and Engagement

Brian Hultgren, Research Administration

Sarah Ward, Research Finance

Target Completion Date

September 30, 2023

Finding 2022-007

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services

Pass-Through Entities: University of Iowa (Assistance Listing No 93.397), Massachusetts General Hospital (Assistance Listing No 93.853), and UCB Pharma, Inc. (Assistance Listing 93.866)

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos: 93.350, 93.393, 93.394, 93.395, 93.397, 93.837, 93.847, 93.853, and 93.866

Award Numbers: Various

Award Periods: Various

Corrective Action Planned

Management will review alternatives for documenting the approval of allowability of internal service charges on awards.

Information Technology (IT) implemented corrective actions as planned following completion of the 2019 audit. Those corrective actions require that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. IT will continue to supplement these corrective actions with additional communications about expectations, and retrospective confirmations of ongoing work to ensure appropriate documentation exists for both new and ongoing work.

The intake processes for other internal service providers will be reviewed and enhanced as needed to ensure appropriate documentation supporting the request for services is captured and retained.

Persons Responsible for Corrective Action

Sean Corcoran, Section Head – Information Technology, Research Applications

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Kristine Williams, Operations Administrator – Research Administrative Services

Target Completion Date

October 31, 2023